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Introduction 
Despite development in surgical techniques, chemotherapy and radio-
therapy, most malignancies of the central nervous system are still devas-
tating tumors with a poor prognosis. For example, median survival of 
patients with malignant gliomas (astrocytoma, oligodendroglioma or 
mixed rype) is roughly 12 months and only 5 % of the patients survive 
more than 5 years after diagnosis (1, 2). Fifty % of astrocytomas are ryped 
as glioblastoma multiforme, the most malignant fonn of glioma (3). 
Glioblastoma account for 15-23 % of all intracranial tumors and have a 
very poor median survival of 6 months with conventional therapy (3-7). 
Metastases account for 15-30 % of all intracranial neoplasm's and de-
velop in 25 to 30 % of all cancer patients (8-10). The overall median sur-
vival time after surgery followed by radiation therapy in solitary metastatic 
lesions ranges from 9 to 23 months, depending on the rype of primary 
cancer (10-15). The prognosis in patients with multiple metastases, how-
ever, is much worse (15). Lepto-meningeal metastases from solid tumors 
are of increasing importance in neuro-oncology, because of the increasing 
frequency and the severe neurologic disabiliry it causes (16, 17). About 
0.8 to 8 % of patients with cancer develop leptomeningeal metastases and 
median survival in these patients after radio- and chemotherapy ranges 
from 7 to 24 weeks (9, 10, 18). 
The response rate to standard therapy in Central Nervous System (CNS) 
cancer is limited for several reasons. First, invasive growth and the pres-
ence of multiple tumor locations limit the feasibiliry of total resection in 
cerebral and spinal cancer (19). Second, radiotherapy and chemotherapy 
are limited in their use due to relative resistance of most tumors and side 
effects in surrounding brain tissue (20, 21). Refinements in neurosurgical 
technique, radiation therapy (including brachytherapy and stereotactic 
radiosurgery) and conventional chemotherapy are therefore unlikely to 
provide dramatic improvement in tumor control and survival. New ap-
proaches should overcome toxic side effects of current regimens, control 
tumor growth and increase survival in patients. 
Gene therapy is a recently developed strategy which in theory might fulfill 
these aims. Gene therapy involves the delivery of a therapeutic gene to 
target cells or tissue were it has to be transcribed to messenger RNA 
(mRNA) and finally should result in the presence of a therapeutic protein. 
The delivery of a therapeutic gene should correct genetic abnormalities or 
provide new functions in a cell. Gene therapy strategies are being devel-
2 lmroduction 
oped for the treatment of inherited diseases (e.g. ioborn errors of metabo-
lism, Duchennes disease, Cystic Fibrosis), acquired diseases (e.g. AIDS) 
and show iocreasiog potential for the treatment of several malignancies 
(22). In gene therapy approaches for cancer, genes have been developed 
which after transfer io malignant cells will iocrease its susceptibility to any 
form of destruction or will restore normal growth pattern. They ioclude 
genes encodiog for cytokioes (e.g.; TNF, GM-CSF, IL--2, IL--4), tumor 
suppressor genes (P53) and "sensitiziog" genes (e.g.; suicide genes en-
codiog Thymidioe Kinase (see chapter 2), Cytosine Deamioase, Cyto-
chrome P450). Theoretically, intracellular iotroduction of genes coding 
for cytokioes will increase immunological response to the tumor cell. 
Transfer of tumor supressor genes into the nucleus on the other hand, will 
restore normal cell functions. Sensitiziog genes encode for proteios which 
form a tumor cell specific toxic substrate after admioistration of a non-
toxic drug. In other approaches, tumor neovasculature is targeted io order 
to obtain growth inhibition. The aim in these "genetic" approaches is that 
tumor cells are specifically killed, while normal surroundiog healthy tissue 
is spared. This could have some significant advantages over current treat-
ment modalities (radio-, chemotherapy) for the treatment of CNS tumors. 
Although gene transfer methods need further improvement, data from 
recent clinical trials usiog gene therapy for the treatment of glioblastoma 
and braio metastases have revealed regression io tumor volume (23, 24). 
The iocreased ioterest io this promising therapy has generated many ex-
perimental data to further improve gene therapy strategies and gene deliv-
ery systems. In this thesis we will present and discuss advantages and 
limitations of different genetic transfer methods and elaborate on suicide 
gene therapy strategies for CNS cancer therapy. 
CHAPTER 1 
Methods of Gene Transfer 
Methods of gene delivery by vehicles or vectors to target cells and tissue 
have been developed ranging from direct injection of naked DNA to the 
delivery via recombinant viruses (25). Although each technique has its 
own advantages and limitations, low toxicity, safety and efficient gene 
transfer are the main concerns of every method. After DNA is delivered to 
the nucleus, either integration or non-integration will take place depend-
ing on the transfer system used (25). Theoretically, following stable inte-
gration of the transgene into the genome of the target cell, the gene will 
consequently pass to all daughter cells after replication. E.g., integration 
(intrachromosomally) of therapeutic genes into bone marrow stem cells, 
may result in correction of all progeny and result in life-long correction of 
the disease (Fig 1). 
Figure 1 Intrachromosomal expression 
Therapeutic gene is transmitted to 
daughter cells after cell division 
This can be achieved by using retroviral vectors. After gene transfer by 
delivery methods which don't result in stable integration of the gene, for 
instance adenoviral vectors, the non-integrated extrachromosomal genes 
will be 'diluted out' if cell division takes place (Fig. 2). 
Figure 2 Extrachromosomal expression 
Therapeutic gene is 'diluted' during 
cell division 
Extrachromosomal trans genes will therefore exerr only transient expres-
sion in a mitotically active cell population. Depending on the strategy 
used, methods aiming at shorr or long lasting gene expression can applied. 
Genetic engineering of cells can take place ex vivo and in vivo (26) 
(Fig. 3). 
Figure 3 Gene therapy - procedures 
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In the ex vivo approach, cells are aspirated or surgically removed, cul-
tured, irradiated if necessary, and returned to the patient after gene trans-
fer. This method is currently used in cancer vaccination studies and for 
transduction of hemopoietic cells and hepatocytes. The in vivo approach 
involves the direct introduction of the vector into cells or tissues. Gene 
delivery to mammalian cells can be accomplished by non-viral and viral 
methods (Table 1). Both methods have their advantages and disadvan-
tages (Table 2). The different vectors will be discussed shortly. 
Non-viral gene delivery methods: 
Naked DNA 
Purified genes or recombinant DNA can be administered to various cells 
and tissues in vitro and in vivo (27-38). After transfer to the nucleus, the 
administered DNA will reside mainly extrachromosomally where transla-
tion and transcription can take place. Purified naked DNA can be trans-
ferred in vitro by calcium-phosphate transfection, electroporation or 
microinjection (25, 39). Naked DNA in vivo is delivered by direct injec-
tion, needle-free injection devices or by the 'gene gun' in which DNA 
coated microparticles are bombarded under high pressure into tissues (40, 
41). DNA delivery to arterial endothelium has been demonstrated with an 
intravasive hydrogel impregnated balloon catheter (42). Although direct 
DNA administration provides an easy, safe method and transfer of large 
gene constructs can also be achieved, transfer efficiency and expression 
levels are relatively low. Enhancement of DNA delivery in vivo can be 
achieved by preinjection of the target tissue with hypertonic sucrose or 
myotoxins (35, 43, 44). 
Ligand mediated transfer 
Gene transfer efficiency can be enhanced by attaching the trans gene to a 
ligand capable of binding to a specific target cell receptor. This can be 
achieved by linking DNA to a covalently bound ligand-polylysine complex 
(45-54). After administration, the ligand interacts with specific receptors 
on the target cell, leading to receptor mediated internalisation of the li-
gand-gene complex into the cell. In addition, aspecific ligands with spe-
cific receptor affinity like transferrine (targeting hematopoietic cells, 
pulmonary epithelium, 48, 49, 52), asialo-orosomucoid (hepatocytes and 
heptoma cells, 45, 46, 55 , 56), surfactant B (lung, 54), anti-thrombo-
moduline (lung, 50), tris-galactosil (liver, 55), and folate (tumor cells, 51) 
have been developed to target gene transfer into desired tissue. 
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Cationic lipids and liposomes 
Lipids are known to cross cell membranes very efficiently and are there-
fore used as vectors to deliver DNA to the cell. Cationic lipids are able to 
form complexes via ionic interaction with negatively charged DNA (57) 
(Fig. 4). These cationic liposome-DNA complexes have been demon-
strated to deliver several genes to tissues in and ex vivo (33, 57-78). The 
cationic liposome-DNA complex fuses with the plasma membrane, after 
which the complex is transported via endosomes to the nucleus were it 
will mainly reside extrachromosomally (Fig.4). Liposome-DNA com-
plexes provide relatively high gene delivery efficiency and are used in sev-
eral clinical trials for cancer and cystic fibrosis (79). 
For in vivo use, the complex has been administered intravenously for sys-
temic application, by aerosol to reach lung tissue or via intravascular bal-
Ion catheters to reach endothelial cells at specific location (33, 57-90). 
Figure 4 Infection with cationic liposomes 
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The rapid degradation of DNA within the cytoplasmatic endosome after 
endocytosis is a major limitation for non viral gene delivery. Methods to 
enhance release from the endosome before these organelles fuse with in-
tracellular lysosomes may increase gene transfer efficiency to the nucleus. 
Since adenoviral particles are known to induce endosomal degradation 
Methods of Gene Transfer 7 
during adenoviral infections, addition of these particles to the DNA has 
resulted in increased gene transfer efficiency into mammalian cells (91). 
The adenoviral particle-induced endosomal degradation resulted in the 
release of the co-internalized DNA into the cytoplasm of the cell (92). 
The addition of adenoviral particles together with complexes for ligand 
mediated transfections has shown to increase gene delivery 100 to 1000 
fold (51, 52, 93-99). In other gene delivery methods, virusparticles are 
attached via polylysine (100, 101) or a streptavidine-polylysine complex 
(102) to the DNA, thereby also increasing endocytosis into the cell. In-
creased endocytosis can also be achieved by binding Influenza virus he-
magglutin to the complex (103). Due to the large size of the adenoviral-
DNA complex and relative high concentration of adenovirus needed for 
effective transfer in vivo, this method has not been employed effectively in 
vivo yet. 
Polymers 
Polymers are used to enhance tissue specific bioavailability and delivery of 
genes to target cells. In addition to cationic lipids, cationic dendrirner-
DNA complexes have been developed which exhibit efficient gene delivery 
in several cells in vitro(104). Addition of several peptides to the den-
drimer-DNA complex has further enhanced delivery by increasing en-
dosomal release (104). 
Table 1 Most commonly used methods of gene transfer 
Non-viral gene transfer methods 
naked DNA (administration by: CaP-transfection, 
electroporation, microinjection or gene gun) 
ligand mediated 
cationic lipids and liposomes 
endosomal release enhancement 
polymers 
Virus mediated 
Retrovirus 
Adenovirus 
Adeno-associated virus 
Herpes Simplex virus 
other viruses 
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Viral gene delivery methods: 
Several recombinant viruses have been developed to deliver genes to tar-
get cells. These recombinant viral vectors make use of the natural ability 
of viruses to infect host cells. Recombinant viruses are vety effective in 
gene delivery and are therefore promising vectors. The wild-type cycle of 
each virus is discussed, followed by the basic principle of recombinant 
construction. 
Recombinant Retl'Ovirns 
Retroviruses are diploid positive strand RNA viruses. After infection of 
the target cell the RNA, is transcribed to DNA by reverse transcriptase 
which is carried as a protein in each viral particle (105). During replica-
tion of the host cell, the pro-viral DNA enters the nucleus were it inte-
grates randomly into the host genome. Subsequently, via normal cellular 
transcription and translation processes, spliced versions of the mRNA 
copies are generated which encode for the retroviral proteins gag, pol and 
env. After assembling the diploid positive strand RNA, the virusparticles 
is bud offftom the cell, starting a new wild-type life cycle (105) (Fig.5). 
The retroviral vectors most commonly used for gene therapy are derived 
from Murine Leukemia Virus (MuLV). The virus genome consists of 
9200 base pairs (=9.2 kb) with a central region (8 kb), encoding for 
retroviral proteins (gag, pol, env), which can be replaced by recombinant 
genes (106-108). If the gag, pol and env genes are replaced by a recombi-
nant gene, the virus is still able to integrate the therapeutic gene into the 
DNA of the target cell. However, since the genes encoding viral proteins 
are missing, the infected cell is unable to generate new viral particles. 
Retroviruses lacking the gag, pol and erv gene are so called 'replication 
defective viruses'. The retroviral genome contains long terminal repeats 
(LTR's) which are specific sequences on both ends of the genome and are 
responsible for gene expression (promoter) and gene integration (Fig.6). 
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Figure 5 The retrovirus life cycle 
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The recombinant virus is generated with the help a so-called packaging 
cell line. The vector is transduced into a cell line (packaging cell line) 
which has been engineered to produce the necessary retroviral gag, pol 
and env proteins RNA transcripts that encodes for the complete retroviral 
genomes (109-121) however cannot be packaged in the viral particles 
(Fig.6). In packaging cell lines that produce viruses that can infect tumor 
cells the MuLV genes gag and pol are combined with env from another 
strain (4070A), to change the ecotropic envelope into an amphtropic en-
velope, which allows infection of human and other mammalian cells. This 
packaging or vector producing cell line (VPC) is capable of excreting rep-
lication defective retroviral vectors without giving rise to replicative com-
petent retroviruses (RCR). The replication defective retroviral vector is 
able to tranduce target cells which eventually wi11lead to trangene expres-
sion (Fig.6). Although generation of RCR has been reported, most exist-
ing packaging cell lines today do not result in generation of RCR and are 
therefore suitable for human use (111,114,117). Titers varying from 10' 
to 10' virus particles/ml can be achieved depending on different tech-
niques and packaging cell lines used (119,120,122,123). After purifica-
tion of the medium, cell free batches of retroviral vectors can be obtained. 
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Figure 6 Recombinant retrovirus life cycle 
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Alterations in binding sites by attaching or incorporating ligands on the 
envelope of the retroviral vector have increased target cell specificity (124-
127). Another approach to target a vector to tissue is the use of specific 
expression enhancers and/or promoters (128, 129). Retroviral vectors are 
mainly used to transduce cells ex vivo (130, 131) because of their relative 
instability in vivo. Efficient transduction in several tissues was only ob-
served after direct vector injection with hlgh titers (132-135). Although 
limited survival of producer cells following in vivo inoculation has been 
observed, direct injection of these cells into rumor tissue has resulted in 
some improvement in gene delivery as compared to purified virus (136) . 
Retroviral vectors are only able to transduce dividing cells to achleve sta-
ble integration of the delivered gene. Thls may be an advantage in treating 
patients with genetic or chronic diseases, but also carries the risk of inser-
tional mutagenesis when the viral derived DNA is randomly integrated 
into onco- or onco-suppressor genes. Although very unlikely, introduction 
of a gene into the germ line can theoretically also occur during application 
in vivo (108, 137-139). Furthermore, RCR whlch could be generated in 
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VPC's through recombination has been shown to induce hemopoietic 
malignancies in rodents and immunosupressed primates in certain condi-
tions (138). The MuLV derived retrovirus however is not known to in-
duce any pathology in humans and is considered to be a safe vector (140). 
Clinical trials have thusfar not shown any side effects due to the applica-
tion ofretroviral vectors (1l1, ll4, ll7). 
Recombinant Adenovirus 
Wild-type adenoviruses are non-enveloped double stranded DNA viruses 
which attach with their fiber proteins to permissive cells (141). After ad-
sorption, the virus is taken up in a cytoplasmic endosome were it is disso-
ciated and "uncoated" (142-144). The double stranded viral DNA is then 
transported to the nucleus where translation to mRNA takes place. After 
translation, the mRNA is translated to viral proteins. The viral DNA is 
not integrated into the host cell genome. Finally, after reassembling in the 
nucleus, the newly generated adenoviruses are released by cellular lysis 
(145) (Fig.7). The viral DNA genome of the wild type adenovirus is 36 
kb long with inverted terminal repeats (ITR), which are specific DNA 
sequences on each side of the genome. These repeats are responsible for 
packaging the viral DNA into capsids (146). 
Figure 7 The adenovirus life cycle 
endosome 
entrance 
The genome is divided in early (E1-E4) and late regions (L1-L5) which 
encode for viral proteins. The E1 region is responsible for activation of 
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other early genes and thereby for replication of the virus (147). The E3 
region encodes for proteins which block cell surface expression of viral 
proteins thereby diminishing immune response (148). The E2, E4 and 
late region proteins have several functions in transcription, gene regulation 
and virus replication (147,149-151) (Fig.8). 
Figure 8 Topography of the adenovirus genome 
Ela Elb L1 
E2b 
El aJElb: transcription regulation 
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E3 
E4: involved in DNA replication, late gene expression and host-cell shut-off. 
L 1: encode majority of virion capsid proteins 
Recombinant adenoviruses used for most gene therapy studies, including 
the studies reported in this thesis, are derived from the subgroup C ade-
noviruses types 2 and 5, which are known to induce self limiting, mild 
respiratory tract infections (145, 152). These viruses have been exten-
sively studied and the complete sequences of both viruses have been de-
termined (153). 
Recombinant adenoviruses are constructed by replacing the El region by 
a therapeutic gene (154-156). Deletion of the El region allows for up to 
3.2 kb offoreign DNA to be cloned into the adenoviral vector. Briefly, the 
gene of interest with the promotor of choice is constructed into a bacterial 
plasmid with adenoviral sequences on both sides. Subsequently, the plas-
mid is linearised and cotransfected with a linearised wild type adenovirus 
genome into a cell line, e.g. human embryonic kidney cell line (293), har-
bouring the complementary El region (157, 158). The linearised plasmid 
and the wild type adenovirus contain specific complementary base pairs at 
one end after linearisation. After transfection, intracellular homologous 
recombination will generate infectious viruses containing the wild type 
adenovirus genome with the El region replaced by the gene of interest 
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(Fig. 9). In addition, the E3 region can also be deleted to create more 
space for insertional genes (159). However, increased host cell immune 
response was observed after administration of E3-deleted vectors i" vivo 
(160). 
Figure 9 Generation of recombinant adenovirus 
m adenovirus ID Wild-type adenovirus-S 
Plasmid 
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/ 
GENE E3 
293 cell 
Recombinant adenovirus 
A transduced cell line e.g. a human embryonic kidney cell line (293), har-
bouring the complementary El region, is used to generate recombinant 
adenoviruses (157, 158). El deleted recombinant adenovirus is able to 
replicate within these cells after infection and are released into the culture 
medium after cellular lysis (Fig. 1 0). The virus can then be obtained after 
purification and ultracentrifugation (155) (Fig. 1 0). Cell infection with 
recombinant adenovirus leads to trans gene expression without formation 
of newly generated adenoviruses, since the El region is deleted. Recom-
binant adenovirus has the advantage that it is stable, a cell free virus can 
be obtained to administer directly via multiple routes (ex vivo, aerosol, 
intracranial, Lm., Lv.) (155, 157-159), and high titers (10"_10" IU) can 
be obtained. The virus can infect a broad range of dividing and non-
dividing cells (145) and insertional mutagenesis or integration into the 
germ line is unlikely because the DNA is not integrated into the host's cell 
genome. Although high expression levels can be achieved, the expression 
of genes is usually transient due to host immune responses or extrachro-
mosomal 'gene dilution' in a dividing cell population. 
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Figure 10 Preparation and propagation of recombinant adenovirus 
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Figure 11 Recombinant adenovirus life cycle 
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A limitation in the use of these vectors could be the preexisting immunity 
to adenoviruses types 2 and 5 in the general population. Also repeated 
injections may lead to direct complement mediated inactivation after two 
or more administrations (161). Another disadvantage may be the immune 
response to viral proteins expressed on the hosts cell surface after infection 
(162). Future additional modifications and deletions in regions of the 
virus genome should increase space for larger inserts and decrease im-
mune response directed to cell surface expressed adenoviral proteins 
(162-165). However, complex cell lines or helper virus containing all 
complementary essential viral proteins will be necessary for their genera-
tion. 
Recombinant Herpes Simp/ex Virus 
The herpes simplex virus 1 (HSV -1) is a double strand, enveloped, non-
integrating DNA virus of 152 kb. After transcription in the nucleus and 
translation in cytoplasm, the wild-type virus is released by fusion of trans-
port~vesicles with the cell membrane (166). The virus is a common 
pathogen in humans which occasionally can induce encephalitis (166). 
Most of the viral functions are known and the complete genome has been 
sequenced (167). The wild-type genome consists of two identical genetic 
sequences (Ul and U2) bound by inverted repeats (a' and a, b' and b, c 
and c') (167). Most viral genes encode for cytotoxic proteins which partly 
cause cell death during virus replication. 
Recombinant, replication incompetent HSV-I viruses have been con-
structed in which many of "non-essential cytotoxic" genes have been de-
leted or mutated to decrease virulance of the virus (168-175). Recently, 
mutant viruses, which are able to replicate in dividing but not in non-
dividing cells, have been developed for cancer gene therapy (175). Re-
combinant HSV-l can be generated by transfecting a plasmid containing 
the trans gene, replication and encapsidation sequences of the virus into a 
HSV-l infection permissive cell. After superinfection with (mutant repli-
cation defective) HSV-l helpervirus, packaged vectors containing the 
transgene, and replication defective HSV-l virus are produced after re-
combination in a 0.1 to 1.0 ratio (172-176). Another approach for gen-
eration of recombinant HSV-I viruses has similarities with production of 
adenovirus vectors (177-180). Essential genes deleted from the virus 
genome is supplied in a producer cell. After superinfection with helper 
virus, recombinant HSV-I can be obtained. With these methods titers 
varying from 10' to 10' cfufml can be achieved. The vector can be admin-
istered ex vivo or by direct injection in vivo (173, 175, 180-197). Recom-
binant Herpes Simplex virus is relatively stable and has a large capacity to 
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accommodate therapeutic genes. After infection, the transgene is not inte-
grated and the virus is able to infect dividing and non-dividing cells. The 
trans gene expression, however, is transient and only moderate expression 
levels can be attained. At present, the virus is of limited value for gene 
transfer due to the cytotoxicity of the viral proteins in mammalian cells. 
The vector further habours the risk of wild-type virus generation and re-
activation of pre-existent latent viruses after in vivo application. 
Adeno-associated vims 
The adeno-associated (AA V) single stranded DNA virus is a 'defective' 
parvovirus with a 4.7 kb genome (198). The wild type virus integrates 
after infection into the host's cell genome where it remains in a latent state 
(199-204). Activation of the virus will only occur after superinfection of 
the cell with (helper) adenovirus or herpes simplex virus (205-210). The 
virus is not associated with any human disease and is therefore, a safe 
vector for application in humans (211). AAV contains two genes, cap and 
rep which encode the viral proteins. The protein coding domain is flanked 
by two inverted terminal repeats (ITR's) (212-221). 
In a recombinant AA V plasmid, the protein coding domain is replaced by 
a therapeutic gene. (222-225). The complementary rep and cap genes are 
provided by another plasmid. For production of recombinant AA V, both 
plasm ids are transduced into a permissive cell. After infection with helper 
adenovirus, recombinant AA V's are produced and released during cell 
lysis. Newly generated vectors can be concentrated and purified on cesium 
chloride gradients. This packaging system gives rise to titers ranging from 
10"-10" infectious particlesfm!. 
The virus can be administered ex vivo or by direct injection and is able to 
transduce a large population of dividing and quiescent cells (225-227). 
The virus is stable and probably remains episomal in non-dividing cells 
and integrates after the cell enters the S phase (224). For unknown rea-
sons, the wild type virus has a preference for an integration site in one 
region of chromosome 19 (228, 229). Unfortunately the recombinant 
virus does not have this preference. The small genome and the limited 
space for insertional genes (4.7 kb) are major drawbacks in this vector 
system. Preexisting immunity in 40 to 80 % of adults, probable presence 
of wild-type AA V in the host and possible genetic alteration in infected 
cells could be other disadvantage when considering the use of these vec-
tors in humans (230, 231). 
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Ocher viruses 
Vaccinia vectors have been developed for vaccination purposes and as 
gene transfer vehicle (232-235). The Vaccinia virusis a 186 kb DNA vi-
rus which replicates in the cytoplasma and can infect dividing and non-
dividing cells (236). The present vectors are able to carry at least three 
insertional genes and there is apparently no size limit for the insert. Rela-
tively high levels of trans gene expression can be achieved with a duration 
of about 1 to 4 weeks. The high immunogenecity of the virus makes re-
peated injection problematic but on the other hand an ideal candidate for 
vaccination studies. Vaccinia vectors encoding the HlV-1 envelope have 
been used in clinical trials with apparently no severe side effects (237, 
238). The backbone of the HlV-1 virus itself is an interesting candidate 
for gene therapy in AIDS and other stem cell disorders because of the 
natural tropism for CD4-positive cells (239). 
Other viral vectors under development concern Sindbis/Semliki forest 
virus (240), poliovirus (241), hepatitis B virus (242), influenza virus 
(243), and the MPSV virus (244). 
Table 2 Comparison of gene transfer systems 
Vector Advantage Disadvantage 
retrovirus stable integration dividing cells only 
producer cells necessary 
adenovirus high transduction pre-existing immunity 
efficiency 
high titers 
Herpes Simplex Virus replication in dividing neurotoxicity 
tumor cells 
MV stable integration low titers 
non viral safety profile low efficiency in vivo 

CHAPTER 2 
Suicide Gene Therapy for 
Malignant eNS Tumors: Review 
Introduction 
Several experimental strategies are being employed in gene therapy for 
CNS tumors. Genes are delivered to malignant cells or tumor vasculari-
sation to induce cell kill or growth control. They include genes encoding 
for sensitizing enzymes (enzymes which can convert non toxic drugs into 
toxic drugs), cytokines and oncogene suppression proteins. Also combi-
nations of genes are used to obtain an anti-cancer effect. Most of the 
transgenes are delivered via viral vectors, although in vaccination studies 
also cationic liposomes are also used as vehicles. The vectors are usually 
injected directly into the tumor mass or intrathecally in the cerebral spinal 
fluid (CSF). Recently, investigators have transduced experimental rat 
brain tumors via intra-arterial (carotid artery) delivery of the vector in 
combination with mannitol to open the blood brain barrier (195, 245). 
This method has the advantage that multiple intracerebral tumor foci can 
be transduced. Leptomeningeal metastases can be transduced effectively 
by intrathecal application of the vector (246, 247). The vehicle is trans-
ported via the CSF flow to the total neuraxis, where transduction of tu-
mor foci takes place. In this chapter, the literature is reviewed for 
experimental suicide and other drug sensitizing gene therapy studies in the 
treatroent of CNS tumors. 
Drug sensitivity 
Intracellular delivery of enzymes that mediate the formation of a cytotoxic 
drug from a non-toxic pro-drug is a pharmaCOlogical method which has 
been used for many years. This basic principle is now also used for gene 
therapy strategies. A vector with a transgene encoding such an enzyme can 
be delivered to the target cells. Expression of the vector will result in in-
tracellular production of a 'drug sensitizing enzyme'. Delivery of a non-
toxic drug to the transduced cells will consequently result in the produc-
tion of a cytotoxic drug which kills the cell. Based on this, this form of 
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gene therapy is also referred to as "suicide gene therapy". The localised 
release of toxic drugs in this approach has the advantage that systemic 
toxicity can be circumvented. The Thymidine Kinase suicide gene (TK) 
and several other genes encoding drugs sensitizing enzymes used in ex-
perimental brain tumor therapy will be discussed. 
Herpes Simplex Thymidine Kinase/GCV System 
The prototype of suicide genes is the Thymidine Kinase suicide gene 
(TK). The gene is derived from the Herpes Simplex virus and encodes for 
the enzyme thymidine kinase (248). This enzyme enhances the phospho-
rylating of nucleoside analogues like non-toxic ganciclovir (GCV) or acy-
clovir, which can be administered intravenously, into a mono-phosphate. 
The mono-phosphate is converted by intracellular enzymes into a GCV-
triphosphate which is a nucleoside analogue. During DNA replication, the 
nucleoside analogue is incorporated instead of the natural substrate de-
oxyguanosine triphosphate (249) (fig. 1). 
Figure 1 Suicide TK-gene transfer: principle 
HSY·tk 
Ganciclovir (GCV) GCY·p j Cellular kinases 
GCY·P(3) 
This introduction prevents DNA elongation by inhibiting DNA po-
lymerase which eventually results in cell death during replication. As the 
nucleoside analogue is only incorporated during cell division, non dividing 
cells are not affected by this mechanism. CNS malignancies are therefore 
ideal candidates for this approach, since the majority of brain cells sur-
rounding these tumors are non-dividing. The efficiency of this approach 
has been mainly subscribed to a so-called "bystander effect" (250). It has 
been demonstrated that only 3 to 10 % of cells in vitro and 10 to 70% of 
cells in vivo transduction is necessary for 100 % tumor cell kill (251-253). 
Other in vivo experiments showed tumor disappearance with a mixture of 
90 % untransduced and 10 % transduced cells after GCV administration 
(136, 254). Due to this bystander effect, not all malignant cells have to be 
transduced with the TK gene to be eredicated after GCV treatment. 
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Several mechanisms have been described to explain this ''bystander ef-
fect". Cell-cell interactions or "gap-junctions" between transduced and 
non transduced cells seemed to be important for intercellular transport of 
toxic products (248, 251, 253-256) (Fig. 2). Cells killed by the HSV-
TKlGCV mechanism undergo apoptosis. Endocytosis or phagocytosis of 
apoptotic vesicles by untransduced cells has also been shown to result in 
death of untransduced cells (251, 253). An additional role in vivo has 
been subscribed to the killing of endothelial cells of the tumor vascular 
system. Disruption of the blood supply to the tumor will eventually result 
in cell kill and necrosis (257). An enhancement of an immune response 
due to expression of foreign genes (HSV-TK) has also been suggested to 
contribute to the anti-tumor response in vivo (193, 258). 
Figure 2 Bystander effect 
Target cells 
10 .. ~8 i i ~6 GCV·3P t 
GCV 
Vectors used for HSV-TK/GCV systetn 
Retrovirus vectors employing the HSV-TKIGCV system 
The use of a retrovirus has the advantage that only proliferating cells are 
transduced with the TK trans gene which decreases possible toxicity or 
gene delivery in tissue directly surrounded by tumor. Marker gene studies 
have demonstrated that direct injection of retrovlral vectors in experi-
mental rat brain tumors resulted in a low transduction efficiency of<O.l % 
(259). This has been partially subscribed to the instability of the vector in 
vivo. Although direct intra tumoral injection of retrovirus vector producing 
cells increased the transduction efficiency to 10 %, producer cell survival 
in vivo is rather low (5-7 days) (259, 260). Survival of the producer cells 
could be enhanced in immunocompromised animals and in animals 
treated with dexamethasone and was most probably caused by the sup-
pression of an anti-immune response against these cells (261, 262). 
Retrovlral vectors harbouring the TK gene have been studied in vitro and 
in vivo in Fischer rats bearing 9L gliosarcoma cells as solid brain tumors 
(136, 193,258,261,263-265) and as leptomeningeal metastases (247, 
266). Generally, increased survival or decreased tumor growth indicated 
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the effectiveness of the HSV-tklGCV system in these studies (Table 1,2). 
There was some variation in the response between the viruses used and 
animal survival (Table 1,2). This may be related to differences in retrovi-
rus titers used, number of injected producer cells, immunosuppression by 
corticosteroids, the volume of the tumor at the beginning of therapy, GCV 
dosages administered, and length of GCV treatment. Tumor regression 
using the HSV -tklGCV system has also been observed in nude mice 
bearing subcutaneous HSV-TK transduced tumors (267). 
No significant toxicity was observed after intracerebral or intrathecal in-
jection of retroviral HSV-TK producer cells in rats and non-human pri-
mates (268-270). 
A major disadvantage in the use of retroviral vectors is the relative large 
amount of producer cells that has to be injected to obtain a therapeutical 
effect in animal models (136, 261, 271). This could lead to volume con-
straints and CSF flow disturbances in a clinical situation. Other draw-
backs could be the immunogenic properties of the producer cell, the 
relative low titers of the recombinant retrovirus, and the fact that these 
vectors cannot infect quiescent, non-dividing, tumor cells. 
Adenovirus vectors employing the HSV-TKIGCV system 
Adenovirus vectors have the advantage over retroviral vectors that high 
titers can be obtained and that both dividing and non-dividing tumor cells 
can be infected. The vectors have been studied in experimental brain tu-
mors (264, 272-276), and leptomeningeal metastases (246) in immuno-
competent rat models. Additionally, the vector was also tested in nude 
mice carrying C6 brain tumors (277). In these experiments, tumor cells 
were injected stereotactically into the brain. When tumor growth was as-
sessed, adenovirus vectors containing the HSV -TK gene were injected 
directly into the tumor. Since the adenoviral infection process only takes 
several hours and the transgene is not integrated and almost immediately 
expressed, GCV was administered already after 12 to 24 hours. Excessive 
'dilution' of the extrachromosomal trans gene by cell division is thus pre-
vented by generating immediate cell kill. 
Prolonged survival or tumor regression in rats with brain tumors (264, 
272-277) or leptomeningeal metastases (246) was observed by several 
investigators using the adeno-TKlGCV system (table 1, 2). Variation in 
animal survival between the different observers was most probably caused 
by the differences in amounts of injected adenoviral particles, tumor vol-
ume at the beginning of therapy, immunosuppression, GCV dosages ad-
ministered, and length ofGCV treatment (table 1,2). 
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Significant toxicity was not observed in any of these experimental models 
after intra tumoral or intrathecal administration of the adeno-TK virus 
although some normal brain cells were also transduced by adenoviral 
vectors (158, 245, 278-285). However, normal brain cells are not affected 
by the HSVrrK system because of their a-mitotical behavior. Direct in-
tracerebral injection of adenoviral vectors in rat brains demonstrated that 
titers higher than 10' pfu's recombinant adenoviruses were able to induce 
inflammation (158, 278-280). Others however, reported already signifi-
cant immune reactions in rodents after intracerebral injection of 10' ade-
novirus particles (286). Differences in titer measurements and the 
presence of replication competent adenovirus may eventually explain 
these different findings. In another experiment, Byrnes at a!. (161) dem-
onstrated that gene expression after adenoviral gene transfer persisted in 
the brain for at least 2 months, without inducing chronic inflammation. 
However, subsequent systemic exposure of the virus was able to induce a 
cell-mediated immune response in the CNS. 
Only limited neurotoxicity after intracerebral injection of an recombinant 
adenovirus in the brain was reported in non-human primates by several 
investigators (281, 282). Goodman et a!. (287), however, reported severe 
toxicity in the brain of a baboon after adeno-tklGCV treatment. Especially 
primates treated with high-dose (1,5xlO' pfu's) adeno-tk and subsequent 
GCV treatment died or became moribund. Necrosis was found at the 
injection sites. Intracerebral injection of lower dosages (7.5xlO' pfu's) of 
adeno-tk resulted in minor lesions like cystic cavities or microscopic foci 
of necrosis at the injection site. It was suggested that that the immuno-
genic adenoviral proteins were partially responsible for the pathological 
changes. Severe toxicity found in baboons treated with high dosage of 
adeno-tk was not observed. 
HelPes Simplex vectors employing the HSV-TKfGCV system 
Recombinant Herpes Simplex vectors have been proved to be effective in 
experimental brain tumor therapy (180-182, 191, 192, 194, 288-290). 
The recombinant Herpes Simplex vectors used for the experimental 
treatment of brain tumors are constructed by inducing one or more muta-
tions in viral genes (e.g. thymidine kinase (195), ribonucleotide reductase 
(291), dUTPase (194) encoding for proteins for replication or neuroviru-
lence. These proteins (thymidine kinase or ribonucleotide reductase) nec-
essary for replication of the Herpes Simplex virus also occur in 
mammalian (tumor) cells and are upregulated during normal cell mitosis. 
During cell division the mutated virus can obtain the complementary 
protein from the infected cell. This will lead to viral replication and sub-
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sequent cell death. The use of this virus for CNS malignancies could 
therefore have some major advantages over other vectors since propaga-
tion of new viruses is restricted to dividing cells (292). 
First generation recombinant Herpes Simplex derived vectors were mu-
tated in the thymidine kinase gene and established an anti-tumor effect in 
several experimental brain tumor models (175, 192, 2SS). However, the 
virus was associated with encephalitis, especially in immuno-incompetent 
animals (290). Some decrease in neurovirulence could be obtained by 
other mutation of the virus genome (lSI, 191,290,293). 
HSV mutants with an intact thymidine kinase gene have shown an effec-
tive anti-tumor response to experimental rat brain tumors (ISO, IS2, 294) 
after GCV administration (Table 3). This thymidine kinase intact mutant 
has the advantage over TK-negative vectors that the virus can be killed at 
any time during therapy after administration of GCV. Recently, second 
generation HSV viruses with multiple mutations but with intact thymidine 
kinase gene have been developed. The virus showed reduced neuroviru-
lence and has also the advantage that the risk of wild-type generation is 
reduced (194). 
Intra-arterial (carotid artery) application of the virus combined with 
opening of the blood brain-barrier by mannitol (195) or bradykinin (260) 
has shown HSV transgene delivery to experimental brain tumors in vivo. 
The aim of these studies was to deliver the vector selectively to one or 
more tumor foci within the brain which is difficult to achieve with direct 
intra tumoral injection. Despite promising results in experimental animal 
models, the vector still causes mortality in treated animals (195) and se-
vere immune reactions and cytotoxicity in mammalian cells (291) and 
CSF (292). The potential risk of wild-type HSV regeneration and activa-
tion of latent HSV-l viruses when single mutated vectors are injected are 
other problems to overcome before human trials are considered. 
Adeno-associated virus (AA V? vectors employing the HSV-TKIGGV system 
Recombinant AA V vectors harbouring the TK gene have mediated effi-
cient gene delivery in an human medulloblastoma model, dissiminated in 
the CSF of nude rats (295). Survival or tumor regression have not yet 
been reported. 
AA V vectors have the advantage that they are able to infect quiescent 
(296) as well as dividing cells (225-227). Administered GCV will conse-
quently kill all TK transduced tumor cells whenever they start to prolifer-
ate. The low titers that can be obtained after isolation of the virus are still 
a major problem to overcome for efficient gene transfer in vivo. 
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Other genes inducing drug sensitivity: 
Cytosine deaminasel5-jluorocytosine system 
The fungal and bacterial enzyme cytosine deaminase (CD) is able to con-
vert the non-toxic 5-fluorocytosine (5-FC) into the toxic metabolite 5-
fluoro-uracil (5-FU) which is frequently used as a chemotherapeutic drug 
(297). 5-FU inhibits RNA and DNA synthesis, resulting in the killing of 
dividing and non dividing tumor cells. It has also been demonstrated that 
the system has a strong ''bystander effect" (298). 
Adenovirally delivered CD to 9L rat gliosarcoma cells has been demon-
strated to kill tumor cells effectively in vitro after 5-FC administration 
(299). Effectivity in vivo and toxicity to surrounding non-dividing brain 
tissue has to be assessed. 
Cytochrome P450 2B1/cyclophosphamide system 
The liver specific P450 cytochrome enzyme is able to convert the antican-
cer drug cyclophosphamide into the metabolites acrolein and toxic pho-
phoramide musterd (300, 301). These metabolites cause DNA 
interstrand crosslinkages regardless the phase of the cell cycle. Cell kill is 
consequently induced in mitosis (302). Cyclophosphamide has been used 
as an chemotherapeutic drug in brain tumor therapy unsuccessfully 
caused by poor penetration of the blood brain barrier and severe side ef-
fects (303). 
To increase sensitivity of cancer cells to cyclophosphamide, the cyto-
chrome P450 gene was delivered retrovirally into C6 rat brain tumor cells 
(304). A 40-fold increase in cell kill was observed in vitro after admini-
stration of cyclophosphamide. Direct delivety of recombinant retrovirus 
harbouring the P450 gene into established brain tumors (C6) in nude rats 
followed by cyclophosphamide treatment resulted however in low anti-
tumor response (304) and was probably due to the low transduction effi-
ciency of retrovirus in vivo. Ex vivo P450 transduced 9L rat gliosarcoma 
cells on the other hand, demonstrated growth inhibition subcutaneously 
and intracerebrally in rats after intra-peritoneal cyclophosphamide injec-
tions (305). 
The Escherischia coli gualline-phosphoribosyltransjeraseI6-thioxanthine system 
The enzyme guanine-phosphoribosyltransferase (GPT) mediates the con-
version of 6-thioxanthine (6-TX) into 6-thioxanthine monophosphate. 
The 6-thioxanthine monophosphate is metabolized by cellular enzymes 
into 6-thioguanine monophosphate which inhibits cellular DNA synthesis 
(306). Following retroviral delivery of the gene encoding for GPT, C6 
26 Chapter 2 
glioma cells were effectively killed after 6-TX treatment in vitro (307). In 
vivo experiments are in progress. 
Clinical trials 
Clinical trials using gene therapy for malignant brain tumors have been 
conducted or are being employed at present in North America and 
Europe. Next to patients with primary brain tumors and secondary me-
tastasis from systemic cancer such as melanoma, lung and breast cancer 
also pediatric patients with progressive or recurrent primary supratentorial 
malignant brain tumors are or have been randomized for phase I/II clinical 
studies (23, 79, 263, 269, 308-311). In the first clinical study using the 
HSV-tklGCV system, retroviral producer cells were injected stereotacti-
cally via multiple injections into the tumor followed by Lv. GCV treat-
ment (269). The first published results of this study showed that gene 
transduction efficiency into tumor tissue was very low, although it has 
been reported that about 50 % of the patients showed significant tumor 
regression on MRI in the early period after treatment (23). The tumor 
regression may result from either the bystander or an immune effect. 
Some patients demonstrated transduction of peripheral blood Iymfocytes 
and in all patients a minimal antibody titer against the producer cells was 
observed (23). Two patients in the study suffered from a preoperative 
hemorrhage. Effects of the second clinical study (308) has reported men-
ingeal inflammation, pancytopenia, seizures and severe headache as side 
effects. Increase of survival in patients with brain tumor, has not been 
reported yet in both studies. 
In a phase 1 clinical trial for the treatment of leptomeningeal metastases, 
retroviral producer cells were injected intrathecally (312) followed by in-
travenously GCV treatment. This study was temporarily closed after tran-
sient meningeal inflammation in the first patient. 
Adenoviral vectors have gained importance as a HSV-tk vehicle in cancer 
gene therapy because its advantages over retroviral vectors. Several centers 
are already using or starting to use the vector in clinical trials for malig-
nant brain tumor therapy (79, 311, 313). 
Conclusions and Future Prospects 
Effective in vivo brain tumor therapy is at present restricted to viral vec-
tors. Recombinant retroviruses have shown in phase I/II studies to be a 
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relative safe vector. In addition, tumor regression using the HSV-tklGCV 
system was observed in human brain tumors. However, low retroviral 
titers, low transduction rates, the non-infectibility of quiescent tumor cells 
and the use of producer cells however, are still major problems to over-
come. Studies with recombinant adenoviruses will demonstrate the possi-
ble potential in CNS malignancies. They are able to infect a wide array of 
quiescent and dividing tumor cells and the chances of mutagenesis are 
low. Gene transfer is efficient and the virus can be applied immediately to 
the tumor. Other recombinant viruses like HSV-l and AA V vectors are 
theoretically ideal vectors for cancer therapy but need further develop-
ment. 
The method of vector application will play an crucial role in the effective-
ness of experimental gene therapy in brain tumors. Direct intratumoral 
injection has limitations in large, "spreading", tumors like glioblastoma. 
In future trials vectors will be administered post-operatively in the tumor-
bed after bulk resection (313). Since malignant brain tumors like glio-
blastoma usually reoccur at the resection site, regrowth could theoretically 
be delayed or prevented. However, tumor progression at distant sites is 
not prevented. Arterial administration in combination with opening of the 
blood brain barrier may also be of value in future gene therapy treatment 
of CNS malignancies (195). Targeting of tumor neovascularisation has 
the potential for effective anti-cancer strategy, but needs further develop-
ment. 
Treatment for leptomeningeal metastases by means of gene therapy has 
shown to be effective after direct intrathecal administration of the vector 
or vector producing cells (246, 247, 266). Intrathecal injection of retrovi-
rus producer cell in humans however, has shown meningeal inflammation 
(312). Toxicity after intrathecal injection of other vectors has to be evalu-
ated further in clinical trials. 
Limitations seen in clinical trials have to be adequately addressed before 
beneficial clinical effects can be expected. Although effective gene transfer 
can be achieved in vivo, the immune response against several recombinant 
viruses may result in severe side effects. Construction of vectors which will 
decrease immune response to viral proteins will be necessary. 
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Aims of this thesis 
• To asses transgene expression in human or rat brain tumor cells in vitro 
after infection with recombinant adenovirus. 
• To asses trans gene expression in rat brain tumors and leptomeningeal 
metastases in vivo after infection with recombinant adenovirus. 
• To investigate human or rat brain tumor cell survival in vitro after in-
fection with recombinant adenovirus containing the HSV -tk and sub-
sequent Ganciclovir treatment. 
• To investigate rat survival with experimental brain tumors or lep-
tomeningeal metastases after infection with recombinant adenovirus 
containing the HSV-tk gene and subsequent Ganciclovir treatment. 
• To compare rat survival with experimental brain tumors after treat-
ment with either recombinant adenovirus or retrovirus producer cells 
containing the HSV-tk gene and subsequent Ganciclovir treatment. 
• To investigate the differences in transgene expression and tumor cell 
kill in vitro, using recombinant adenoviruses containing either an MLP 
or CMV promotor. 
• To investigate the differences in rat survival with brain tumors or lep-
tomeningeal metastases in vivo, using recombinant adenoviruses con-
taining either an MLP or CMV promotor. 
• To asses the histopathology in the rat brain after intracerebral injection 
of adenoviral vectors harbouring the HSV-tk gene and subsequent 
GCV administration. 
• To asses the systemic spread of recombinant adenovirus after in-
tracerebral injection. 
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Abstract 
Tmnsfer of a herpes simplex virus derived thymidine kinase (HSV-tk) gene 
into brain tumor cells and subsequent Ganciclovir (GCV) treatment has 
been shown by others to be an effective treatment in mts with intmcerebmlly 
inoculated 9L gliosarcomas. Mechanism of action and reproducibility are 
however still a matter of debate. We have used the same model to test the 
therapeutic effects of both retrovirus and adenovirus mediated tmmfer of the 
HSVtk gene followed by GCV treatment. Survival time of mts with in-
tracerebml 9L tumors was significantly prolonged after a single administra-
tion of adenovirus canying a HSV-tk gene as compared to controls. 
Retrovirus mediated gene transfer also resulted in significantly prolonged 
survival time when recombinant retrovirus producing cells were transplanted. 
Direct injection of the recombinant retrovirus, HSVtk expressing cells, virus 
producing cells without GCV administration and recombinant retrovirus-
LacZ or IL-2 producing cells did not result in tumor cell kill. In the present 
study, no significant difference in survival of 9L brain tumor canying rats 
was found after treatment with adenovirus as compared to retrovirus medi-
ated HSVtk mediated gene transfer and subsequent GCV treatment. 
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Introduction 
Despite surgery, radiation therapy and chemotherapy, the prognosis of 
glioblastoma in humans has not substantially been improved in the last 
decades. The overall median survival time of patients with malignant as-
trocytomas is approximately 10 months. Two years after diagnosis only 10 
% of the patients is alive (33, 35, 18, 6). A new approach for the treat-
ment of brain tumors may be application of virus-mediated transfer of the 
Herpes simplex virus thymidine kinase (HSV-tk) gene into tumor cells 
(10). Expression of the HSV-tk gene renders dividing cells sensitive to 
GCV. GCV is converted into triphosphate-GCV, a chain terminator of 
DNA synthesis. (22, 23). A promising aspect of this form of gene therapy, 
designated as the ''bystander effect", is that after GCV treatment more 
tumor cells are killed than those that are transduced with HSV-tk (39, 10, 
31,7, 19). Non-dividing cells that have been transduced with the HSV-tk 
gene are not killed by GCV. As brain tumors are embedded in essentially 
non-dividing brain tissue, these tumors are good candidates for this ther-
apy. Other investigators showed improved survival and decreased tumor 
size of rats carrying intracerebral transplants of glioma (9L) cells after 
treatment with either a recombinant retroviral vector or adenoviral vector 
containing the HSV-tk gene followed by GCV therapy. (10, 26, 31, 9). 
The mechanism of action is still incompletely understood. TK-transduced 
tumor cells for example, may increase immunogenecity (41) and destruc-
tion of proliferating TK-transduced tumor vasculature after GCV admini-
stration influences tumor growth (32). 
In the present study, the effects of recombinant retrovirus and adenovirus 
mediated transfer of the HSV-tk gene into brain tumor cells followed by 
treatment with GCV have been studied. 
Material and Methods 
Tumor cells 
The 9L rat gliosarcoma brain tumor (a kind gift from Dr. KM. Hebeda, 
Dept. Experimental Neurosurgery, Free University Hospital Amsterdam, 
The Netherlands) was induced by N-methylnitrosurea in Fischer 344 rats 
and characterised by Weizsaecker et ai., '(44). The U251 human glioma 
cell line (29, 37) was obtained from Dr. C.H. Langeveld (Dept of Phar-
macology, Free University Hospital Amsterdam, The Netherlands). Tu-
mor cells were cultured in Dulbecco's modified Eagle's medium 
supplemented with penicilline (100IU/ml; Gibco), streptomycine (50 
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mg/ml; Gibco), 10% fetal calf serum and non-essential amino acids. The 
cells were grown at 37'C; 5% CO, in 80 or 175cm' flasks (Nunclon). 
Figure 1 Physical map ofpMLP.TK, the plasmid that was used to 
generate the recombinant adenovirus IG.Ad.MLP.TK. 
Aatll 
Sail 
pMlp.TK 
AdS: nudeotides 1-458 of the adenovirus type 5 genome 
__ "._ Xbal 
BamHI 
mlp: major late promotor, tpl: tripartite leader sequence. The mlp and tpl are derived from 
adenovirus type 2 
HSV~tk: Herpes Simplex Virus type 1 thymidine kinase 
SV 40: Simian Virus 40 poly-adenylation sequence (nt 2533-2668 of the SV 40 
genome) 
BgllI-Scal fragment of adenovirus type S; nt 3328-6092 of the adenovirus type 
5 genome 
AMP; Ampicillin resistance gene 
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Recombinant vectors: 
1. Adenoviral vectors 
The Herpes Simplex Virus type I thymidine kinase sequences were de-
rived from plasmid pHAI40 (gift from Dr. A. Berns, Netherlands Cancer 
Institute, Amsterdam), by PCR amplification using primers TK-l (5'-
CTCTAAGCTTGAAGCGCGCGTATGGCTTCG-3' and TK-2 (5'-
ACACTCTAGAGTGTTTCAGTTAGCCTCC-3'). 
The TK sequences were cloned after digestion with restriction enzymes 
HindIII and XbaI and ligated into pSP65 (Promega) and sequenced com-
pletely. As compared to the published sequence (20) 3 differences exist: 
on position 16 (G instead ofT), 126 (T instead of C), 267 (A instead of 
G). Recombinant adenoviruses harbouring the HSV-tk (IG.Ad.MLP.TK) 
were made from plasmid pMLP.TK (Fig. I) in which HSV-tk expression 
is under the direction of the adenovirus derived major late promoter and 
transcription is tenninated by the SV40 poly-adenylation signal. 
A similar construct harbouring the firefly luciferase (luc.) gene (45) was 
made by replacement of HSV-tk in pMLP.TK by luc. Recombinant vi-
ruses were generated by co-transfecting 293 cells with Sall linearized 
pMLP.TK and the large ClaI fragment of wild-type Ad5 DNA. Recombi-
nant viruses were plaque purified twice, propagated and titrated according 
to standard procedures (30). Ad.RSVpgal recombinant adenovirus har-
bouring the Escherichia coli lacZ gene encoding p-galactosidase and pre-
ceded by the nuclear localisation signal (38) was obtained from Dr. M. 
Perricaudet (Institut Gustave Roussy, Villejuif, France). Titers deter-
mined by end point titration of the virus batches ranged from IxlO IO to 
lxl0"ru. 
2. Retroviral vectors 
pLXSN (21) was digested with BamHI, blunted with Klenow enzyme and 
digested with NheI. The 1452 bp NheIlBamHI fragment was ligated to the 
98 bp StuIlNheI fragment from pLNSX (21) in a three-part ligation with 
pUC19 vector backbone obtained after digestion of pSFG-tpa (Kindly 
provided by I. Riviere and R. Mulligan, Whitehead Inst. for Biological 
Research, Cambridge, MA) with NheI. The resulting construct, pLec, was 
digested with XhoI, blunted with Klenow and subsequently digested with 
Bam HI. After dephosphorylation using calf intestine phosphatase, this 
fragment was ligated to a fragment containing the coding region of the 
Herpes simplex virus type 1 thymidine kinase gene (HSV-l tk) obtained 
from pMLP.TK by digestion with HindIII, blunting with Klenow and 
digestion with BamHI. The resulting viral vector was named pLTk. 
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pLTk was linearised with Bs.WI, partially digested with BeoRI and 
dephosphorylated with CIAP. The 5' part of the tk gene was then reintro-
duced as a BeoRIIBs.WI pcr fragment obtained after amplification of the 5' 
part of the tk gene in the vector TNFUS69 (36) using the primers 
TKkozUp: 5'-CGGAATTCGCCGCCACCATGGCTTCGTACCCC-
GGCCACAG-3' and TkDo-l: 5'-CGGCTCGGGTACGTAGACGA-
TATCG-3' followed by digestion with BeoRI and Bst\'I1I. The resulting 
retroviral construct, named pLTKkoz only contains the coding sequences 
of the HSV-l tk gene with an optimized Kozak sequence (16) around the 
start codon. The NheI fragment from pLTKkoz was introduced into the 
unique NheI site from pSKlZiplBMo+PyF101 to create construct pIGTk. 
pSKlZiplBMo+PyF101 has been generated by subcloning of the ClaI-
BeoRI fragment from pZipDMo+PyFI0l(N-) into the pBluescript 
(Stratagene) vector. pZipDMo+PyFI0l(N-) is described in Valerio et aI., 
'(1989). PA317 packaging cells were co-transfected with pIG-TK and an 
expression construct containing the neo' gene by CaPO. coprecipitation. 
Individual colonies were isolated and tested for virus production by su-
pernatant infection of TK- Rat-2 fibroblast cells. Supernatant harvested 
for 2 hours at 37°C from a 75% confluent culture of the cell clone used in 
this study contains 5xl0' pfu's/ml. No replication competent retrovirus 
was detected in a marker rescue assay. A TK positive cell line, designated 
TK+RV- that did not produce retroviral vectors was generated by co-
transfection in PA317 cells of a non-viral expression construct, harboring 
the HSV-tk gene under control of the murine phosphoglycerate kinase 
promoter. Both the TK+RV- non producer cell line and the IG-RV-TK 
virus producer cell line were killed 100% by GCV concentrations as low 
as O.lmM. 
A retroviral LaeZ producer cell line was kindly provided by Dr. R. C. 
Hoeben (Lab. of Mol. Carc, Univ. of Leiden, The Netherlands). This 
retroviral vector was made according to procedures described in Hoeben 
et aI., (1991). 
A PA317 packaging cell line producing retrovirus encoding human IL-2 
was constructed by standard procedures (34), using cDNA encoding for 
human IL-2 (cDNA was kindly provided by Dr. Schrier, Depart.of Clin. 
Oncol. Acad. Hosp. Leiden, The Netherlands). The gene was ligated into 
the pMFG retroviral construct digested with Neal I BamHI (12). Infec-
tion of a rat lung tumor cell line with the IL-2 virus resulted in succesful 
gene transfer into more than 25 % of the cells. The IL-2 activity was 
measured by a bioassay. The IL-2 producing cell clone had a maximum 
activity of 200 U/24 hoursl 10' cells. 
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In vitro studies 
The 9L rat glioma and human U251 glioma cells were plated in 24 well 
culture dishes (Costar) at a density of 10' cells! well. Triplicate wells were 
infected with Ad.RSVpgal at multiplicity of infections (m.o.i.) of 0, 1, 10 
and 100. Three days after infection, duplicate wells were used to measure 
LacZ gene expression by assessing p-galactosidase activity as described by 
Norton at al. (1985). Three days after infection, remaining wells were 
stained with X-Gal (27). Killing efficiency of the suicide gene transfer was 
tested according to Chen et aI., (9). 9L rat glioma and human U251 
glioma cells were plated in 24 well culture dishes (Costar) at a density of 
10' cells! well and infected with IG.Ad.MLP.TK at m.o.i. 0, 1, 10 and 
100. Twenty-four hours later, the infected cells were treated with GCV or 
PBS at a concentration of 10 mg/ml. After 72 hours, the surviving cells in 
quadruplet wells were trypsinised and surviving cells detennined by trypan 
blue exclusion method, were counted. 
In vivo studies 
Fischer 344 rats, weighing 200-400 grams, were randomised, anesthetized 
with ether and placed in a stereotaxic frame. A burr hole was made 1 mm 
in front of the bregma and 2 mm lateral of the midline. 4xl0' 9L rat- glio-
sarcoma cells in 1 III of Hank's buffered saline were injected by a microli-
ter syringe (27 gauge needle; Hamilton) in the left forebrain, 4 mm ven-
tral of the skull. The cells were injected over a period of 2 minutes. The 
needle was slowly retracted and the burr hole was closed with bonewax 
(Braun). The skin was closed with 9 mm auto clips. The same procedure 
and coordinates were subsequently used to inject recombinant adenovirus. 
A volume of 10 ;11 was infused over 5 minutes along the needle track (1 pi 
per 0.5 mm) starting 1 mm deeper than the injected tumor cells. 
Ad.RSVpgal was injected 6 days after tumor inoculation in dosages of 
2.5xlO', 2.5xl0',and 2.5xl0' pfu 's (n=6!group) in a volume of5 Ill. PBS 
(5 Ill) was injected into the tumor as control (n=6). 3 days after tumor cell 
implantation different amounts ofIG.Ad.MLP.TK or IG.Ad.MLP.luc as 
control were injected into the tumor in 8 different groups of rats; 5.10' 
(n=6), 10' (n=16), 10' (n=10) and 10' (n=10) IU of IG.Ad.MLP.TK 
and 5.108 (n=7), 10' (n= 12) IU ofIG.Ad.MLP.luc. It was calculated that 
the different groups treated at 3 days with IG.Ad.MLP.TK and 
IG.Ad.MLP.luc were infected with an m.o.i. of 5000, 1000, 100, 10 and 
5000, 1000 respectively, by assuming a population of 10' tumor cells at 
the respective time points of virus inoculation, based on a cell doubling 
time of 18-20 hours (44). Fourty eight hours after the injection of the 
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virus, the rats received twice a day 15 mglkg ganciclovir (Syntex) or PBS 
intraperitoneally for ten days (Fig. 4). 
After death, the brain tumors were dissected from surrounding tissue and 
weigbed. To examine the LacZ expression at different time points, three 
animals per group were sacrificed on day 5 and day 11 after virus injec-
tion. The rats were perfused via the left ventricle with ice cold 4% 
paraformaldehyde, the brains were removed and postfixed in the same 
solution. The brain was cut in 2 mm sections, washed thoroughly with 
PBS and stained with X-Gal for 3 hours at 37'C, essentially as described 
by Bout et aI., 1994. After staining and photography the samples were 
embedded in paraffin, cut into 2 mm sections and counterstained with 
hematoxilin, phloxin and saffrane. 
For the study of retroviral vectors, 3 days after tumor cell implantation, 
5xl0' IG-RV-TK producer cells were infused over 15 minutes into the 
tumor (n=10) in a volume of 20 ml along the needle tract. Control ani-
mals were injected with PBS (n=5), 5xl0' retrovirus LacZ producer cells 
(n=5), 5xl0' TK+RV- cells (n=5), supernatant of IG-RV-TK producing 
cell line (n=5) and 5xlO' retrovirus IL-2 producer cells (RV-IL2; n=5), 
all in a volume of 20 Ill. From eigbt days after tumor cell implantation the 
rats were treated twice a day with 15 mg/kg GCV intraperitoneally for ten 
days. A control group was treated with PBS instead of with GCV follow-
ing injection of HSV-tk virus producer cells (n=5). Survival data of the 
adenovirus and retrovirus injected rats were presented as Kaplan - Meier 
plots (15). The log rank test was applied for statistical analysis of survival 
data. 
Results 
In vitro results 
After infection in vitro with Ad.RSVpgal at an m.o.i. of 100, almost all 
U251 tumor cells and approximately half of 9L tumor cells were positive 
for LacZ at 3 days after infection. (fig. 2a, 2b - appendix). Following in-
fection with an m.o.i. of 10 and 1 only a few transduced tumor cells were 
observed. Non transduced tumor cells (controls) did not show blue pre-
cipitates in the nucleus, but there was a sligbt blue staining in the cyto-
plasma of glioma cells, probably caused by endogenous p-galactosidase 
(data not shown). Dead cells, morphological changes or other cytopathic 
effects were not observed at an moi of 100 in both tumor cell types. p-
galactosiase activity in the human tumor cell line at an m.o.i. of 100 was 
higber than in the rat tumor cells (Table 1). This was in agreement with 
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the experiment (Fig.2 - appendix) where the number of blue cells was 
higher in U251 than in 9L tumor cells. Cultured human U251 glioma 
cells were more sensitive to infection with IG.Ad.MLP.TK and subse-
quent GCV treatment than the rat tumor cells (Table 2.). Only 5 % of the 
U251 tumor cells survived at m.oj. 100 as compared to 40 % of the rat 
glioma cells. 
Table 1 
Tumor cell 
U251 
9L 
p-Galactosidase Activity in Cultured Glioma Tumor Cells 
following infection with Ad.RSVbgal 
M.O.1.0 
o 
o 
M.O.1. 1 
2.4 
0.7 
M.O.1.10 
1.1 
1.1 
M.O.1. 100 
52.2 
6.3 
The table shows the mean values (n=2) of p~galactosidase activity/ mg protein (x1000) at differ-
ent m.o.i's and different tumor cell cultures in vitro 72 hours after infection with Ad,RSVpgal. The 
p-galactosidase activity per well was corrected for background activity produced by the tumor 
cells. Cultured human U251 and rat 9L gliosarcoma were infected with AdRSVpgal at different 
m.o.i .. M.o.i was calculated assuming a cell population of 3x105 cells at confluency. 
Table 2 
Tumor cell 
9L 
9L 
U251 
U251 
Glioma Cell Survival (in %) after Infection with 
IG.Ad.MLP.TK and Subsequent GCV or PBS Treatment 
Treatment M.O.I.O M.O.l.l M.O.l.lO M.O.l100 
PBS 100 87 79 84 
GCV 79 67 65 40 
PBS 100 115 71 67 
GCV 81 29 16 5 
The table shows the mean percentages (n=4) of glioma cell survival after infection with 
IG.Ad.MlP.TK and subsequent GCV or PBS treatment. 9l rat glioma and human U251 glioma 
cells were plated in 24 well culture dishes at a density of 1 xl 0 4 cells! well and infected with 
IG.Ad.MlP.TK at m.o.i. 0, 1, 10 and 100. Twenty-four hours later the infected cells were treated 
with GCV or PBS at a concentration of 10 mglml. After 72 hours the surviving cells in quadruplet 
wells were trypsinised and counted by trypan blue exclusion method. 
Adenoviral marker gene slIIdies 
Five days following infection of the intracerebral brain tumor, brain sec-
tions showed LacZ staining of the tumor region. The blue precipitates 
were mainly localised in tumor regions adjacent to normal brain tissue 
(Fig. 3a - appendix). 
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Tumors injected with PBS did not show any blue precipitates (data not 
shown). At II days after infection, a few blue patches were still seen in 
tumors injected with 2.5x10' IU. Tumors injected with PBS or with lower 
amounts of virus (2.5xIO' and 2.5xlO' IU) showed no blue precipitates at 
this time point. The latter was probably due to a 'diluting' effect in the 
dividing tumor cell population. Microscopical examination of in vivo 
transduced tumors, revealed blue precipitates in the nucleus of the malig-
nant cells. A large proportion of the tumor cells expressed l3-galactosidase 
(Fig. 3b - appendix). Brain cells adjacent to the tumor showed also some 
blue nuclear precipitates, but no dead cells, no mophological changes and 
no other cytopathic effects were observed (Fig. 3c - appendix). 
In vivo gene therapy 
Rats treated with IG.Ad.MLP.TK at an m.oJ of 5000 and 1000 showed 
significantly prolonged survival time as compared to the rats given 
IG.Ad.MLP.luc or IG.Ad.MLP.TK without GCV treatment (log rank 
test, p<O.OI, Fig. 4). Two animals in the group treated with m.oJ 5000 
and I animal in the group treated with m.o.i 1000 died of superficiallep-
tomeningeal tumor (Fig. 4) which was caused by spill of tumor cells 
through the burr hole. Intracerebral tumors were not present in these rats. 
In addition, rats treated with IG.Ad.MLP.TK at an m.o.i. of 100 survived 
18.3 days on the average (Fig. 4) as compared to 15.7 days for the control 
group. The prolonged survival time in this treated group was significant as 
compared to controls (log rank test, p<0.05). Survival of rats treated with 
10' pfu's (m.o.i.of 10) was not significantly different from controls (log 
rank test, p>0.05). 
Figure 4 
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Kaplan-Meier survival curves of rats with brain tumor treated with single doses recombinant 
adenovirus and subsequent GCV administration. Intracerebral injection of tumor cells at day O. 3 
days after tumor cell implantation different amounts of IG.Ad.MLP.TK(TK) or IG.Ad.MlP.luc.(luc.) 
as a control were injected into the tumor in different groups (1 to 8) of rats (n:::61) . Fourty eight 
hours after virus injection 15 mg/kg GCV (G+) or 1 ml PBS (G-) was administered i.p. twice daily 
for ten days. 
1. TKlG+, 5.108 1U, n=6 L-J. 5.luciG+, 5.108 IU, n=7 L __ ). 
2. TK/G+, 1.1O'IU, n~lO L_l. 6. luc.lG+, 1.10'IU, n~6 L __ l. 
3. TK/G+, 1.10' IU, n~10 (---""-l. 
4. TK/G+, 1.10'IU, n~10 ( ........ l. 
7.luc./G-, 1.108 1U, n=6 L __ l. 
8. luc.lG-, 1.10' IU, n~6 L __ ). 
Rats in groups 5 to 8 were not significantly different from each other in survival time (p>O.05; log 
rank test) and are represented as one group L __ ) in the Kaplan-Meier survival curve. The rats 
in groups 1, 2 and 3 lived significantly longer than all control groups (p<O.Ol, p< 0.01, p<O.OS 
respectively, log rank test). Three rats died of superficial leptomeningeal tumor (*). These are 
censored in the survival analysis. 
In all animals that died, the tumor weight was detennined. Tumors in-
oculated with IG.Ad.MLP.TK did not differ in mean weight (0.322 mg 
+0.81 mg) from tumors injected with IG.Ad.MLP.1uc. (0.318 mg + 0.63 
mg). This shows that death ensues when the tumor mass has reached a 
certain volume. It was calculated that the brain tumors at the time of 
death contain approximately 3.2xl 0' cells (assuming that 10' cells weigh 1 
gram). As 4xl0' cells were inoculated, the number of tumor cells in un-
treated rats increased approximately 10' times in 16.7 days, indicating a 
tumor doubling time of approximately 1 day if all tumor cells are dividing. 
The shortest survival time among rats treated with IG.Ad.MLP.TK with 
an m.o.i of 5000, 3 days after tumor cell inoculation was 32 days. At the 
start of the GCV therapy the tumor contained + 10' cells (3 cell divi-
sions). The number of tumor cells after the end of GCV therapy at day 
15, was extrapolated to be 10" indicating that at least 1 log cell kill oc-
curred. The rat that died at 68 days from the brain tumor must have had 
between 1-10 viable tumor cells present after GCV therapy, which corre-
sponds 4 to 5 log cell kill. 
Rats inoculated with a IG-RV-TK producing cell line followed by GCV 
treannent survived significantly longer than any of the 5 control groups 
(p<0.01, log rank test; average survival time control groups: PBS: 15.2 
days; retrovirus LacZ producer cells: 14.4 days; TK+RV- non-producer 
cell line: 14.0 days; supernatant IG-RV-TK producer cell line: 16.6 days; 
IG-RV-TK producer cell line without GCV administration: 16.2 days; 
IG-RV-hIL 2 producer cell line: 14.6 days; Fig. 5). 
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Figure 5 Kaplan-Meier survival curves of rats with brain tumor treated 
with single doses recombinant retrovirus producer cell lines 
and subsequent GCV administration. 
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Intracerebral injection of tumor cells at day O. IG-RV-TK was injected 3 days after tumor cell 
inoculation. One group was injected with IG-RV-TK producer cells (n=lO)~. The controls 
(n=5/ group) were injected with PBS '-----.), RV-LacZ producer cells (--------) TK+RV- non pro-
ducer cells L _), supernatant of IG-RV-TK producer cells L __ ) and RV-IL2 producer cells 
L - - .....J. One group was injected with IG-RV-TK producer cells without subsequent GCV 
treatment (- - - - - -) . Five days after virus injection 15 mg/kg GCV was administered Lp. twice 
daily for ten days. IG-RV-TK treated rats lived significantly longer than controls (p<O.Oli log rank 
test). One rat died of superficial leptomeningeal tumor (*). This rat is censored in the survival 
analysis. 
Eight rats in the group treated with IG-RV-TK producer cells died from 
their brain tumor. One animal with a survival time of 50 days died of su-
perficial leptomeningeal tumor which was caused by spill of tumor cells 
through the burr hole. No intracerebral brain tumor was present. Using 
the same cell population kinetics as above, it appears that also after treat-
ment with IG-RV-TK producing cells I to 5 log cell kill was achieved. 
Although the median survival time (26 days) was less than after treatment 
with 5.10' IU IG.Ad.MLP.TK (39 days) there was no significant differ-
ence in mean survival time between the different treated groups (log rank 
test, p>0.05). 
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Discussion 
Our study shows an efficient adenovirus-mediated gene-transfer into rat 
and human brain tumor cells in vitro at an m.oj of 100. At this m.oj, 
human glioma cells showed a higher level of LacZ expression and p-
galactosidase activity after Ad.RSVpgal infection as compared to rat tu-
mor cells (Fig. 2a, 2b - appendix and Table 1). The in vitro data also 
showed that human U251 tumor cells are more sensiUve to 
IG.Ad.MLP.TK I GCV treatment than 9L rat tumor cells (Table 2).We 
have no satisfactory explanation for this phenomenon, but is most likely 
caused by more efficient adenovirus mediated gene delivery to human 
cells. Effective adenovirus-mediated marker gene-transfer in rat brain 
tumors in vivo was only achieved after injection of 2.5.10' Ad.RSVpgal 
ill. The amount of LacZ positive tumor cells in vivo decreased dramati-
cally in time indicating a 'diluting effect' of extra- chromosomal adenoviral 
DNA in a rapidly dividing cell population. These results are in agreement 
with recently published data of Badie et al.(2) and Boviatsis et aI., (43). 
This indicates that maximum tumor cell kill in vivo after transduction 
with IG.Ad.MLP.TK will only take place if GCV treatment has already 
commenced when the thymidine kinase gene is expressed. In contrast, 
after retroviral gene transfer, stable integration of the recombinant gene in 
the tumor cell DNA will occur and will be retained in all progeny. How-
ever, the therapeutic efficiency of thymidine kinase gene therapy with 
retrovirus has been questioned by Wei et aI., '(1994), since retroviral inte-
gration of the recombinant gene in tumor cells is dependent on cell divi-
sion and the majority of cells in human malignant brain tumors remain in 
GO (resting phase) at anyone time (24, 46). These arguments can not 
hold for the treatment with adenoviral vectors which are also capable of 
transducing non-dividing cells. Whenever such transduced tumor cells 
enter the S phase of the cell cycle, cell death will occur as long as GCV is 
provided. 
Injection with a m.o.i. lower than 100 resulted in ineffective transduction 
and tumor cell kill in vitro in both tumor cell cultures. Our in vivo experi-
ments indicate that an m.o.i. of at least 100 is necessary for effective tu-
mor cell kill following GCV treatment (Fig. 4). Chen et aI., (9) showed 
that adenoviral TK transduced gene expression in the C6 rat glioma cell 
line in vitro continued to increase at multiplicity of infections higher than 
125, where 100 % transduction was achieved using the LacZ gene. It can 
be expected that the amount of adenovirus that can be injected in the tu-
mor will be limited by direct toxicity for surrounding tissue. Intratumoral 
injection of 2.5 xl0' ill's resulted in no cell death, no morphological 
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changes and no other cytopathic effects in the surrounding brain tissue 
measured after 5 days, using light microscopy. Akli et aI., '(1993) found 
that four days after direct intracerebral injection of more than 10' IU of 
adenovirus resulted in detectable cytopathic effects in brain tissue. Our in 
vivo results showed that the distribution of injected virus is predominantly 
limited to the tumor and that only small areas of the surrounding brain 
tissue were infected. Although the virus was directly injected into the tu-
mor, spread through the loose incoherent tumor tissue is apparently more 
effective than within brain tissue where fiber tracts or the glia cells may 
prevent their diffusion (17, 1,3, 11). 
The prolonged survival time of rats treated with IG.Ad.MLP.TK and IG-
RV-TK as compared to control rats demonstrated the effectivity of 
IG.Ad.MLP.TK and IG-RV-TK in this brain tumor model. Our data 
show also that rats injected with IG-RV-TK producer cells live signifi-
cantly longer than control animals, including controls injected with IG-
RV-TK producer cells without GCV treatment. This is in contrast to re-
cently published data by Tapscott et aI., (41) who reported that GCV 
selection is not required for tumor cell kill, implicating an immunologic 
mechanism induced by TK-transduced brain tumor cells. Immunogenic-
ity of in vivo retroviral TK-transduced tumor cells was not observed by 
us, even after in vivo transduction with RV -hJL-2 producer cells. 
With both recombinant viruses, a tumor cell kill was calculated of be-
tween 1 and 5 log. The broad range in tumor cell kill in the different ani-
mals suggest that virus delivery varied widely. Although the viruses were 
injected at the same stereotactic coordinates as the tumor cells, not all 
tumor cells were transduced. Methods of virus delivery to the tumor have 
to be improved. 
In the present study, no significant difference in survival time (log rank 
test; p>0.05) was observed after treatment with IG.Ad.MLP.TK as com-
pared to IG-RV-TK producer cells, indicating that both methods may be 
clinically useful. Other factors may favor the use of adenoviral vectors in 
clinical studies. Recombinant adenoviruses have the advantages that high 
titers can be obtained and that the cell free virus can be administered in 
vivo. Recombinant adenovirus also infects non-dividing tumor cells 
(resting phase) and consequently kill these cells in the S phase of the cell 
cycle when GCV is provided. A disadvantage may be toxicity of adenovi-
rus for normal brain at high m.o.i., although in our study no adverse ef-
fects were seen. 
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Abstract 
We constructed recombinant adenoviral vectors to investigate its potential for 
gene therapy treatment of leptomeningeal metastases. Several human cell lines 
derived from tumors occurring as leptomeningeal metastases infected in vitro 
with recombinant adenovirus containing the luciferase gene, (IG.Ad. MLP.luc.) 
showed high levels of expression. W'hen these human tumor cell lines were in-
fected in vitro with recombinant adenovirus harbouring the HSV-tk gene 
(IG.Ad.MLP. TK), they were highly sensitive to killing by GCv. Transduction 
efficiency of leptomeningeal tumor cells in vivo was assessed by injecting 9L rat 
brain tumor cells into the cerebrospinal fluid via the cisterna magna of Fischer 
rats. After three days, recombinant adenovirus containing the LacZ reporter 
gene (IG.Ad.MLP.LacZ) was injected via the same route. Six days after tumor 
cell injection expression of the reporter gene was observed in tumor cells along the 
total neural axis. Subsequently, rats with leptomeningeal metastases were treated 
3 days after tumor cell injection with IG.Ad.MLP. TK. The next day, ganci-
clovir was injected i.p. for ten days. Rats that developed neurological symptoms 
were killed instantly. The symptom free latency of every rat was determined. 
Rats treated with IG.Ad.MLP. TK and subsequent GCV had significantly 
longer (p<O.OI) symptom free latency than all control groups. 
This study demonstrates the feasibility and efficacy of this therapeutic approach 
in a rat model. Clinically, it should be employed in the palliative treatment of 
patients with lepto-meningeal metastases. 
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Introduction 
The prognosis of patients with malignant leptomeningeal metastases is 
generally poor. Without treatment, the rapidly proliferating malignant 
cells in the circulating cerebro spinal fluid (CSF) cause a large diversity of 
disabling neurological symptoms and the average survival without treat-
ment is reported as 4-6 weeks (15,19,33). Palliative treatment of lep-
tomeningeal metastases aims at long lasting neurologic improvement. 
However, the number of effective drugs that can be administered directly 
in the subarachnoid space is small and systemic administration is often 
limited by drug resistance and toxicity (11). Whole neuroaxis radiother-
apy may cause severe bone marrow depression which may therefore limit 
future additional chemotherapy treatment. New treatment modalities are 
needed for this progressive fatal neurological illness. 
A promising approach for treatment of local tumors is the transfer of the 
Herpes Simplex Virus thymidine kinase gene (HSV -tk) into tumor cells, 
which renders these cells highly sensitive to the toxic effects of ganciclovir 
(GCV) (7,16,17). GCV is phosphorylated by tk-transduced cells which 
interferes with DNA synthesis during cell replication. Since only dividing 
cells are killed by this mechanism, central nervous system (CNS) tumors 
are good candidates for this approach. We and others have already shown 
the effectivity of "suicide" gene therapy in a rat brain tumor model using 
recombinant adenovirus (6,21,31), Herpes Simplex virus (3) or retrovirus 
(7,20,24) harbouring the HSV-tk gene. Since leptomeningeal metastases 
are surrounded by essentially non-dividing tissue, they are also another 
possible candidate for this treatment. Theoretically, injection of recombi-
nant virus into the CSF could transduce multi-focal tumor cells or masses 
throughout the CNS. Direct injection of the viral vector into the 
subarachnoid space is clinically feasible and high concentrations of GCV 
in the CSF can be achieved by systemic administration. 
Ram et al (25) have shown the therapeutic potential of direct injection of 
retroviral-tk vector-producer cells in the CSF of rats with leptomeningeal 
neoplasia. Recombinant adenovirus has the advantage that high titers can 
be obtained and that the cell free virus can be administered directly in 
vivo. Since no producer cells are injected, the risk of CSF obstruction by 
clustering cells can be circumvented. In contrast to retrovirus, recombi-
nant adenovirus also infects non-dividing, quiescent, tumor cells and con-
sequently kills these cells upon their entry into the S phase of the cell cycle 
when GCV is provided. 
In this study, we investigated the feasibility of treating leptomeningeal 
metastases. The sensitivity of malignant human tumor cells, known to 
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metastasize into the leptomeninges was assessed in vitro using a recombi-
nant adenovirus containing the HSV-tk gene. Subsequently, distribution 
and viabiliry of the adenovirus in CSF, and treatment effectiviry in an 
immunocompetent rat leptomeningeal tumor model was tested. 
Materials and methods 
Adenoviral vectors 
Recombinant adenoviruses harbouring the HSV-tk gene (IG.Ad.MLP.-
TK) were made from plasmid pMLP.TK in whlch HSV-tk expression 
driven by the adenovirus derived major late promoter (14) and transcrip-
tion is terminated by the SV40 poly-adenylation signal. The generation of 
IG.Ad.MLP.TK was described elsewhere (31). Similar adenovirus con-
structs containing the firefly luciferase gene (Iuc.) or nls.LacZ gene 
(Escherischia coli LacZ gene preceeded by the nuclear localisation signal) 
were made. The luc cDNA was derived from pRSV.luc (9). pRSV.Iuc was 
digested with HindIIl and SspI, to excise the luc sequence, that was 
cloned in the multiple cloning site of pBluescript (BS) (Stratagene). Sub-
sequently, the HindIIl and Bam HI cloning sites of pMLP.TK were used 
to replace the tk cDNA by the luc sequence derived from pBS.luc. 
The nls.LacZ gene was excised from L7RHbgal (II) with AvrIl and 
BamHI and ligated together with a HindIII - XbaI linker sequence into 
pMLPIO that was digested with HindIII and Bam!. The new construct 
was named pMLP.nls.LacZ/-Ad. The BglII - Seal fragment (nt. 3328 -
6092) from adenovirus rype 5 was ligated into pMLP .nls.LacZ/-Ad after 
digestion with BamHI and Nru!. The resulting construct was 
pMLP.nls.LacZ. 
Recombinant viruses were generated by co-transfecting 293 cells with Sal! 
linearized pMLP. TKlIuc/nls.LacZ and the large ClaI fragment of wild-
type AdS DNA. Recombinant viruses were plaque purified twice, propa-
gated and titrated according to standard procedures (23). Virus titers de-
termined by end point titration ranged from 1xIO lO to IxIO" IU. The 
respective resulting recombinant viruses were named IG.Ad.MLP.TK, 
IG.Ad.MLP.Iuc and IG.Ad.MLP.LacZ. 
Tumor cells 
Tumor cells were cultured in Dulbecco's modified Eagle's medium (9L, 
U251, A549, 518 A2)(Gibco) or RPMI 1640 (GLC-l) (Gibco) supple-
mented with penicilline (100 IU/ml; Gibco), streptomycine (50 mg/ml; 
Gibco), 10% fetal calf serum and non-essential amino acids. GLC-I was 
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cultured in RPMI 1640 (Gibco) The cells were grown at 37'C; 5% CO, 
in 80 or 175cm' flasks (Nunclon). 
Efficiency of gene transfer in vitro 
The rat glioma (9L) and human tumor cells were plated in 24 well culture 
dishes (Costar) at a density of 10' cells/well. Cells in triplicate wells were 
transduced with IG.Ad.MLP.luc at multiplicity of infections (m.o.i.) of 0, 
10, 100 and 1000. Seventy-rwo hours after infection cells were 
trypsinized, centrifuged and resuspended in lysis buffer (100 mM Na-
Phosphate pH 7.8, 8 mM MgCI" 1 mM EDTA, 1 mM DTT, 1 % Triton 
X-IOO, 15 % glycerol). After centrifugation the luciferase activity was 
determined in the supernatant by measuring integrated light emission for 
10 seconds in the presence of 25 mM ATP and ImM luciferin (9) with a 
MGM Optocom II luminometer. Activity was presented as light units 
(LU) per mg of soluble protein (LU/mg). The protein concentration was 
determined by the BIO-RAD DC protein assay kit (Bio-Rad Laborato-
ries). 
Killing efficiency in tumor cells in vitro 
Killing efficiency of GCV after TK-gene transfer was tested according to 
Chen et al.(6). The rat glioma and human tumor cells were plated in 24 
well culture dishes (Costar) at a density of 104 cells/well and infected with 
IG.Ad.MLP.TK at m.o.i. of 0, 10, 100 and 1000. Twenty-four hours 
later, the infected cells were treated with GCV (Syntex) at a concentration 
of 10 mg/ml or PBS (control). After 72 hours, the surviving cells in tripli-
cate wells were trypsinised and determined by trypan blue exclusion 
method. To evaluate killing efficiency ofIG.Ad.MLP.TKlGCV treatment 
over time, 9L tumor cells and U251 tumor cells were plated in 24 well 
culture dishes (Costar) at a density of 10' cells/well and infected with 
IG.Ad.MLP.TK at m.o.LlOO and treated with GCV (10 mg/ml) or PBS 
(control). The surviving cells were determined as described above every 
24 hours for 6 days. 
Leptomeningeal tumor model 
A modified version of the 9L rat syngeneic leptomeningeal metastases 
tumor model was developed (13). Fischer F344 rats were anesthetized 
with ether, shaved suboccipitally and placed in a stereotactic frame with 
the skull in flexion. 4xIO' 9L rat tumor cells in a volume of 30 pi using a 
0.1 ml syringe were injected through the skin, dorsal neck muscles and 
dura mater directly into the CSF of the cisterna magna. The right position 
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of the needle tip prior to cell injection was affirmed by positive CSF aspi-
ration. 
In vivo studies 
Male Fischer 344 rats weighing 2S0-300 grams were anesthetized with 
ether and injected with 4xl0' 9L tumor cells suboccipitally as described 
above. After 3 days, rats were injected via the same route with 1.10' pfu's 
IG.Ad.MLP.LacZ (n=3), 2.10' IV IG.Ad.MLP.TK (n=2S) or phosphate 
buffered saline (PBS, n=22, control) in a volume of 30 J.ll. To examine 
LacZ expression in leptomeningeal tumor cells, rats injected with 
IG.Ad.MLP.LacZ and PBS (n=2) were sacrificed 6 days after tumor in-
jection. The rats were perfused via the left cardiac ventricle with ice cold 4 
% paraformaldehyde, the brains and spinal cord removed and postfixed in 
the same solution. The brain and spinal cord were cut into 2 mm sections, 
washed thoroughly with PBS and stained overnight with X-Gal at 37°C 
for histochemical detection of transduced cells. After staining the sections 
were embedded in paraffin, cut into 2 pm sections and counterstained 
with hematoxilin, phloxin and saffrane. 
Rats injected with either IG.Ad.MLP.TK or PBS received twice a day 
intraperitoneal injections of GCV (IS mg/kg, Syntex, n=IS) or PBS 
(n=30) for 10 days. Rats were observed daily and killed instantly when 
moribund or when neurological symptoms such as paralysis of the legs, 
unsteady gait or incontinence developed. The symptom free period of 
every rat was calculated starting with the injection ofturnor cells on day O. 
The symptom free latency of each group was presented in a Kaplan-Meier 
plot (12). The log rank test was applied for statistical analysis of symptom 
free latency data. 
Sources of supplies and equipment 
The 9L rat gliosarcoma brain tumor (a kind gift from Dr. K.M. Hebeda, 
Dept. Experimental Neurosurgery, Free University Hospital Amsterdam, 
The Netherlands) was induced by N-methylnitrosurea in Fischer 344 rats 
and characterised by Weizsaecker et aI., '(34). The U2S1 human glioma 
cell line (22,28) was obtained from Dr. C.H. Langeveld (Dept. of Phar-
macology, Free University Hospital Amsterdam, The Netherlands). The 
AS49 human lung carcinoma cell line (10) was purchased from Biowhit-
taker (Brussel, Belgium). The GLC-l human small cell lung cancer 
(SCLC) cell line (8) was kindly provided by Prof. Dr. L de Ley (Dept. of 
Clin. Immunology, State University Groningen, The Netherlands) and 
the S18 A2 human melanoma cell line (27 by Dr. P Schrier (Dept. of 
Clin. Oncology Academic Hospital, Leiden, The Netherlands). 
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Results 
In vitro experiments: 
Gene transfer and killing efficiency 
The efficacy of adenovirus mediated gene transfer to human and rat tu-
mor cells was determined by infecting the cells with IG.Ad.MLP.luc. 
Luciferase-activity was detectable in all tumor cells infected at m.o.i. of 
10, 100 and 1000. In all cell lines tested luciferase activity increased with 
the m.o.i. (Fig. I). 
Figure 1 Luciferase actIvity of tumor cells (9L, 518 A2, A549, 
GLC-OI, U251) transduced in vitro with IG.Ad.MLP.luc 
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Tumor cells were plated at a density of lxl04/well and infected with IG.Ad.MlP.luc. at m.o.i. of 
1, 10 and 1000. Seventy-two hours after infection, cells were lysed and luciferase activity was 
determined. Activity was presented as light units (LU) per mg of soluble protein (lU/mg). A. 
m,Q.i. 10. B. m.o.i. 100. C. m.o.i. 1000. 
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Human tumor cells infected with IG.Ad.MLP.luc. showed a 10 to 100 
times higher luciferase activity as compared to the rat 9L tumor cells. The 
highest activity was detected in the U251 glioma and GLC-O 1 small cell 
lung carcinoma cells. 
Cultured tumor cells infected with IG.Ad.MLP.TK were killed effectively 
within 72 hours after treatment with GCV (Fig. 2). 
Figure 2 Survival percentage of tumor cells infected ill vitro with 
IG.Ad.MLP.TK and subsequent treated with GCV or PBS 
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Tumor cells were plated at a density of 1x10
4
/well and infected with IG.Ad.MlP.TK. at m.o.i. of 
10, 100 and 1000. Twenty-four hours later the infected cells were treated with GCV at a concen· 
tration of 1 0 ~Iglml or PBS. After 72 hours, the cells in triplicate wells were trypsinised and sur-
viving cells counted by trypan blue exclusion method. A. 9l rat glioma cells. B. U251 human 
glioma cells. C. GlC-Ol human small cell lung carcinoma cells. D. A549 human non·small cell 
lung carcinoma cells. E. 518 A2 human melanoma cells. 
The cell kill continued to increase after 72 hours as shown in the 9L and 
U251 tumor cells (Fig. 3). The human tumor cells were more sensitive to 
the TK/GCV treatment than the 9L rat tumor cells. At m.o.i. of 10, 100 
and 1000, mean cell survival after 72 hours ranged from 8.5 % -31 %,3.7 
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% -15.5 % and 0 - 10.2 % respectively in human tumor cells as compared 
to a 64.8 %, 39.6 % and 3.7% in rat glioma cells. 
Figure 3 tumor cell survival 
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Survival with time percentages of 9L rat glioma and U251 human glioma tumor cells in vitro 
infected with IG.Ad.MlP.TK and subsequent GCV treatment. Tumor cells were plated at a density 
of lxl04/well and infected with IG.Ad.MlP.TK. at an m.o.i. of 100 and treated with GCV at a 
concentration of 10 Ilglml or PBS. For 6 days, every 24 hours, cells in triplicate wells were 
trypsinised and surviving cells were counted by trypan blue exclusion method. 
In vivo experiments: 
Tumor model 
Rats inoculated with 4xl0' 9L tumor cell developed symptoms between 
16 and 19 days after tumor inoculation. The symptoms ranged from pa-
ralysis of one or more legs, unsteady gait, very poor general or moribund 
condition. Rats died within 24 hours after onset of the symptoms. Micro-
scopic examination of the eNS 6 days after tumor inoculation showed 
infiltration of tumor cells in meninges of cerebrum, cerebellum and along 
the spinal cord. The largest tumor mass was usually observed near the 
injection site. No infiltration of normal brain tissue or spinal cord was 
observed (data not shown). 
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Adenoviral marker studies 
Microscopic examination of sacrificed rats inoculated with IG.Ad.MLP.-
acZ showed expression of the reporter gene in tumor cells all along the 
neural axis. Transduced tumor cells were observed between the meninges 
and surface of cerebrum, cerebellum and spinal cord (Fig. 4a,b,c - appen-
dix). Most transduced cells were observed in the tumor mass near the 
injection site. Few ependymal cells surfacing the cerebrospinal fluid cavity 
showed also some blue nuclear precipitates, but no morphological 
changes or other cythopathic effects were observed (Fig. 4d - appendix). 
No LacZ staining was observed in the brain tissue or myelum adjacent to 
transduced tumor cells. Choroid plexus was stained blue after X-Gal 
staining in both treated and control animals (PBS), which was probably 
caused by a high endogenous Il-galactosidase activity. No further blue 
staining was observed in the CNS of control animals. 
In vivo therapy 
Animals injected with recombinant adenovirus did not show any clinical 
or neurological signs related to vector administration. Rats treated with 
IG.Ad.MLP.TK and GCV showed a significantly prolonged symptom 
free period as compared to control rats (log rank test, p<O.OI)(Fig. 5). 
Control rats had a mean symptom free period (days) of 17.6±1.0 SD 
(PBSI GCV-), 19.4±1.3 SD (PBS/GCV+), 18.9±1.7 SD (IG.Ad.MLP.-
TKlGCV-), as compared to 22.2± 2.0 SD of the treated group. 
The symptoms of control rats ranged from paralysis of one or more legs, 
unsteady gait or very poor general or moribund condition. This was in 
contrast to the treated (IG.Ad.MLP.TKlGCV+) rats which developed 
incontinence and/or paralysis of one or more hind legs without the more 
generalized detoriation seen in the control animals. In 26 % of the treated 
rats, incontinence was accompanied by hematuria. Macroscopic examina-
tion of the CNS of control animals showed superficial massive tumor 
growth in the cisterna magna, compressing cerebellum, brain stem and 
medulla oblongata. Superficially growing small tumor nodules were ob-
served all around brain tissue and in the thoraco-Iumbar region. In treated 
rats macroscopic tumor was only observed in the thoraco-Iumbar region 
which compressed the lower parts of the myelum and cauda equina. Rats 
with incontinence had large 'retention' bladders sometimes filled with 
blood. Hematuria was probably caused by the increase in intravesical 
pressure, thereby causing disruption of blood vessels in the bladder wall. 
Figure 5 Symptom free rats 
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Kaplan-Meier curves of rats with established lepta-meningeal tumors treated with recombinant 
adenovirus and subsequent GCV administration. Rats (n=45) were injected intrathecally with 
4xl04 9L tumor cells. After 3 days, rats were injected via the same route with 2.109 IU 
IG.Ad.MLP.TK or PBS. Twenty-four hours after tumor cell injection 15 mg/kg GCV or 1 ml PBS 
was administered i.p. twice a day for ten days. Rats were killed instantly when moribund or if 
neurological symptoms developed. Rats treated with IG,Ad,MLP.TK and subsequent GCV had 
significantly longer (p<O.Ol) symptom free latency than all control groups (PBS/GCV-, PBS/GCV+ 
and IG.Ad.MLP.TKlPBS). 
Discussion 
Our in vitro results show that adenovirus mediated gene transfer and gene 
expression in various tumor cells known to metastasize to the leptomen-
inges is very efficient (Fig. 1). The data show that the amount of gene 
expression is directly related to increased m.o.i. (Fig. 1). Tumor cell kill-
ing efficiency after TKlGCV treatment was also dependent on m.o.i. (Fig. 
2), indicating that gene expression levels are an important parameter for 
cell kill. The in vitro data also demonstrate that a more efficient transfer 
and expression of genes can be obtained in human tumor cells than in 9L 
rat tumor cells (Fig. 1). The average luciferase activity measured in hu-
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man tumor cells after IG.Ad.MLP.1uc infection was 100 times higher as 
compared to rat tumor cells (Fig. 1). Human derived, malignant cells 
were also more sensitive to killing by IG.Ad.MLP.TK and subsequent 
GCV treatment than 9L tumor cells (Fig. 2,3). This observation is in 
agreement with our previous experiments (31) and is most likely caused 
by a more efficient adenovirus mediated gene expression or delivery to 
human than to rat tumor cells. However, gene expression levels may not 
be the only relevant factor as tumor cell killing efficiency in vitro did not 
always correlate with expression levels of the luciferase gene. U251 glioma 
tumor cells for instance, showed about the same expression levels of lu-
ciferase after 72 hours as in the GLC-I Small cell lung carcinoma cells. 
The latter, on the other hand, were more effectively killed after 
IG.Ad.MLP.TK/GCV treatroent (Fig. 2). This is most likely explained by 
the so called "bystander effect", the phenomenon that more tumor cells 
are killed than are transduced with the HSV-tk gene (3,7,30). Because 
cell-cell interaction and gap-junctions play an important role in the by-
stander effect (I), it is not unlikely that GLC-I small cell lung carcinoma 
cells, which grow in three dimensional non-adhering large floating aggre-
gates (8), are killed more effectively than U251 mono-layer cell cultures. 
In addition, cell cycling time or other factors may also playa role. 
In this study, we used a simplified version of the 9L rat syngeneic lep-
tomeningeal metastases tumor model. Instead of introducing a permanent 
catheter into the upper thoracic subarachnoid space via the cisterna 
magna, as described by Kooistra et al.(13), we have chosen to inject the 
tumor cells directly into the cisterna magna to avoid any damage to the 
CNS, CSF flow obstruction or other problems caused by the catheter. 
With the skull in flexion, injections of tumor cells into the cisterna magna 
of Fischer rats after positive CSF aspiration is accurate and fairly easy. 
This modified model proved highly reproducible in assessing tumor 
growth as all untreated rats developed neurological symptoms between 
day 16 and day 19, with an average of 17.6 days. Although a tumor mass 
was found near the injection site as demonstrated in the 'catheter studies', 
histological examination of CNS showed that a substantial number of 
tumor cells formed multiple foci along the total neural axis (Fig.4 - ap-
pendix), indicating that injected tumor cells were transported effectively 
along the CNS. Furthermore, the model showed to be very useful to 
demonstrate the therapeutical efficacy of a single treatment therapy. A 
similar and reproducible model has been described before in nude rats 
using H-146 SCLC tumor cells (18). 
The in vivo marker studies show that recombinant adenovirus can trans-
duce tumor cells at a distance from the injection point in a relatively large 
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closed compartment (Fig. 4 - appendix). Thusfar, recombinant adenovi-
rus has been used in most studies for direct injection into tissue or tumor 
mass (2,5,21,31). Gene transduction into established lepto-meningeal 
tumor cells using retrovirus producer cells or recombinant adenovirus has 
been published before (25,32), but the majority of transduced cells in 
these studies were in the vicinity of the implanted catheter tip. Our study 
demonstrates that the adenovirus can be transported effectively within the 
CSF, without inducing clinical or neurosurgical symptoms and is not im-
mediately inactivated by humoral or cellular factors. Only few ependymal 
cells surfacing the CSF were transduced using IG.Ad.MLP.LacZ (Fig. 
4B). It is not expected that transduction of ependymal cells or other non 
replicating cells in the CNS with 'suicide genes' will lead to cell kill after 
administration of GCV because they are relatively mitotically inactive. 
Microcopically, no morphological and no cythopathic effects were ob-
served in the CNS. This is in agreement with other data, in which recom-
binant adenovirus was directly injected into brain tissue (30). Whether 
strong immune responses occur in the relatively "immune privileged" 
CNS after recombinant adenovirus injections, is still a matter of debate 
(4,6,29,31). 
As the mechanism of transduction by retrovirus and adenovirus are differ-
ent (31), it is not possible to compare transduction efficiency we obtained 
with those reported after injection of retrovirus producing cells (25). 
The effectivity and safety of a single treatment with IG.Ad.MLP.TK and 
subsequent GCV administration in rats with established lepto-meningeal 
metastases is demonstrated in this study (Fig. 5). The study also shows 
that the therapeutic effect is tkIGCV dependent and not related to an im-
mune reaction against virus transduced cells (Fig. 5). Rats did not show 
any clinical or neurological signs related to the vector and/or GCV ad-
ministration, demonstrating the clinical feasibility of this approach. Since 
higher expression and cell kill are observed in human as compared to rat 
tumor cells (Fig. 1,2,3), it is to be expected that the therapeutic effect in a 
clinical situation will be stronger than demonstrated in this model. Fur-
thermore, leptomeningeal metastases in humans are not as aggressive as 
demonstrated in this model and relatively higher amounts of recombinant 
adenovirus can theoretically be administered intrathecally in humans as 
compared to the limited injection volume in rats. 
The symptomatology and macroscopic tumor location in the different 
groups at death show that developing tumors at a certain distance from 
the injection site can be killed effectively and that systematically adminis-
tered GCV can penetrate into leptomeningeal tumor cells. As tumor cells 
in the CSF of patients with lepto-meningeal metastases can circulate 
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through the CSF causing new tumor nodules it is an important observa-
tion that non-adhering tumor cells were also killed effectively with this 
method as measured in vitro (Fig. 2B). The study demonstrates that re-
combinant adenovirus can be administered safely intrathecally without 
inducing acute neurological or other clinical symptoms. The effectivity of 
gene therapy for leptomeningeal metastases has been shown earlier using 
retrovirus-tk producer cells (25). Although both methods may be clini-
cally useful, the use of recombinant adenovirus has a few advantages over 
injection of retrovirus producer cells. High titers of purified cell free virus 
can be injected directly intrathecally, thereby limiting the volume of ad-
ministered fluid. The number of retrovirus-tk producing cells that can be 
injected into the CSF is limited because of volume constraints and in-
jected cells can theoretically cause CSF obstruction problems. Clinical 
studies with retroviruses have been complicated by severe immune reac-
tions against the producer cells (26). Furthennore, retroviral integration 
of the recombinant tk-gene is completely dependent on mitotically active 
cells whereas recombinant adenovirus can also infect non-dividing 
'quiescent' tumor cells and consequently kill these cells in the S phase of 
the cell cycle when GCV is provided. 
Conclusions 
Our results show therapeutic efficiency and feasibility of recombinant 
adenovirus harbouring the HSV-tk gene in leptomeningeal metastases. 
Clinical application of this approach is considered feasible. 
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Abstract 
Objectives: 
Adenoviral gene transfer and killing efficiency using the TKIGCV mechanism 
was evaluated in human cancer cells occurring as CNS tumors. Effectivity of 
this approach was tested in vitro and in experimental models for brain tumor 
and leptomeningeal metastases in rats in vivo. Recombinant adenoviruses with 
different promoters were compared. 
Methods: 
Adenoviral vectors harbouring a marker (LacZ) or a Thymidine Kinase (TK) 
gene were constructed. Transcription of genes was under the control of either the 
Adenovirus type 2 major late promoter (MLP) or the human cytomegalovirus 
(CMf? immediate early gene promoter. LacZ expression and GCV killing effi-
ciency after TK gene transfer in several human tumor cells was evaluated in 
vitro. The 9L-rat brain tumor and -leptomeningeal metastases model were used 
to determine the effectivity of adeno-TK and subsequent GCV treatment m 
vivo. MLP and CMV containing adenoviral vectors were compared. 
Results: 
Gene expression and tumor cell kill was very efficient in all human tumor cell 
lines tested. The adenovirus containing the CMV promoter showed cytopathic 
effects in cultured tumor cells at high mo;, but also h;gher cell kUling efficiency 
after TKIGCV treatment as compared to the MLP promoter. Although both the 
MLP and CMV vectors showed a significant dose dependent therapeutic effect, 
animals treated with recombinant adenovirus containing the CMV promoter 
showed significantly longer survival time (brain tumors) or symptom free period 
(leptomeningeal metastases). 
Conclusions: 
This study demonstrates the therapeutic efficiency and feasibility of the 
TKIGCVapproach in experimental brain tumors and leptomeningeal metasta-
ses. It also demonstrates that the promoter driving the transgene in an adenovi-
ral vector influences toxicity and efficiency of treatment. 
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Introduction 
Despite extensive surgery, high dose radiation and chemotherapy, mini-
mal improvement in survival has been achieved in most Central Nervous 
System (CNS) malignancies over the last few decades. Glioma, cerebral 
and leptomeningeal metastases remain neoplasm's with very poor progno-
sis (19,20,24,34). The current regimens induce severe side effects and are 
therefore restricted in their use. New treatment modalities are needed 
which increase survival without inducing such severe toxic reactions., 
'Suicide gene therapy' has been shown to be an effective and relatively 
safe new approach for treatment of experimental brain tumors and lep-
tomeningeal metastases (6,10,11,39,40). First, Retrovirus (11,25,31), 
Herpes simplex virus (6,9), and later, Adenovirus (10,27,40) vectors have 
been developed to deliver the Herpes simplex thymidine kinase (HSV-tk) 
'suicide' gene to brain tumor cells. Expression of the HSV-tk renders di-
viding cells sensitive to ganciclovir (GCV). HSV-tk converts GCV into a 
toxic phosphate which acts as a chain terminator of DNA synthesis, which 
will eventually lead to cell death (21,22). Since only dividing cells are 
killed selectively while sparing normal surrounding healthy tissue, treat-
ment of CNS malignancies by suicide gene therapy could have advantages 
over current treatment modalities (radio-,chemotherapy). Adenoviral 
vectors have the advantage that high titers can be obtained, and cell free 
virus can be administered in vivo. Adenovirus does not integrate into the 
genome, thereby reducing the risk of insertional mutagenesis. The vector 
is also able to infect non-dividing quiescent tumor cells and subsequently 
kill these cells upon their entry into the cell cycle when GCV is provided. 
Several investigators (10,27,37,39,40) have demonstrated that treatment 
of experimental glioma and leptomeningeal metastases with adenovirus 
vectors harbouring the HSV-tk gene was not associated with toxicity. Re-
combinant adenoviruses thus have potential to be used as vectors in 'sui-
cide gene therapy' of CNS malignancies in humans. However, adenoviral 
gene expression and tumor cell killing effectivity using the TKlGCV 
mechanism in human glioma cells has not been given much attention yet 
in literature. Since the adenoviral transgene is not integrated into the 
genome, rapidly dividing tumor cells can significantly decrease trans gene 
expression. When clinical use is considered, more fundamental research 
concerning interaction of tumor cell rate division and killing efficiency 
should be investigated. 
In this study, we investigated the feasibility of suicide gene therapy in sev-
eral human tumor cell lines occurring within the CNS as malignancies 
using adenoviral vectors. First, we have used vectors harbouring the LacZ 
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gene to investigate transduction efficiency in vitro in several human tumor 
cells known to occur as glioblastoma, brain metastases or leptomeningeal 
metastases. Subsequently, tumor cell kill after treatment with recombinant 
adenovirus carrying HSV-tk and subsequent GCV administration was 
tested. Treatment effectivity in vivo was assessed in immuno-competent 
rat models for brain tumors and leptomeningeal metastases. Finally, the 
potential of different promoters was investigated. Adenoviral vectors har-
bouring either the Adenovirus type 2 major late promoter (MLP) or the 
human cytomegalovirus (CMV) immediate early gene promoter were 
constructed. \"Ie compared cytopathic effects of the vectors only on cul-
tured cells and cytotoxicity of vector administration and GCV treatment 
in vitro. Furthermore, effectivity of the treatment of tumors was assessed 
in vivo. 
Materials and methods 
In vitro studies: 
Adelloviral vectors 
Recombinant adenovirus containing the TK gene driven by the MLP 
promoter was derived from plasmid pMLP.TK in which HSV-tk expres-
sion is driven by the adenovirus-derived major late promoter and tran-
scription is terminated by the SV40 polyadenylation signal. A similar 
adenoviral construct containing the nls.LacZ gene (Escherischia coli LacZ 
gene preceded by the nuclear localisation signal) was made (pMLP.LacZ) 
Recombinant adenovirus containing the TK gene driven by the CMV 
promoter was made from the pCMV.TK plasmid in which the HSV-tk 
expression was under the control of the CMV promoter. SV40 RNA 
splicing signals (180 bp) containing the late viral protein gene 16s/19s 
splice donor and acceptor signal are in between the promotor and trans-
gene. These sequences were isolated from pCMV nlslLacZ (12). The 
Escherischia coli LacZ marker gene, preceded by a nuclear location signal, 
was cloned by replacing TK in pCMV.TK by LacZ in a plasmid similar to 
pCMV.TK called pCMV.nls.LacZ . 
The adenoviral vectors were generated by co-transfecting 293 cells 
with Sail linearized plasmids (pMLP.TKlLacZ or pCMV.TKlLacZ) and 
the large ClaI fragment of wild type Ad5 DNA. The E3 region was re-
tained in all adenovirus vectors. Recombinant viruses were plaque purified 
twice, propagated and titrated according to standard procedures (28). 
Virus titers determined by end point titration on 911 cells ranged from 
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IxiOIO to IxiOIl Infectious Units (ill) The resulting recombinant viruses 
were named IG.Ad.MLP.TK, IG.Ad.CMV.TK, IG.Ad.MLP.LacZ and 
IG.Ad.CMV.LacZ respectively (Fig. 1). The generation of IG.Ad.MLP.-
TK, IG.Ad.CMV.TK, IG.Ad.MLP.LacZ and IG.Ad.CMV.LacZ have 
also been described in detail elsewhere (13,39,40). 
Figure 1 
Map of the constructed recombinant adenoviral vectors. Shown are the Human Ad 5 DNA can-
taing the expression cassete. The cassette (enlarged) contains either the Adenovirus type 2 major 
late promoter (MlP) or the human cytomegalovirus (CMV) immediate early promoter. The pro-
moter is preceded by an inverted terminal repea~ followed by followed by either the nlsLacZ, 
(Escherischia coli LacZ gene preceeded by the nuclear localisation signal) or Herpes Simplex 
derived Thymidine Kinase (TK) suicide gene. Transcription is terminated by SV40 poly-
adenylation sequences. 
Prom.: ether the CMV or MLP promotor. Transgene: either TK or nlsLacZ gene. 
Ad 5: human adenovirus DNA. ITR: inverted terminal repeat. peA): SV40 poly-adenylation 
sequences. 
Tumor cells 
The 9L rat gliosarcoma brain tumor (a kind gift from Dr. K.M. Hebeda, 
Dept. Experimental Neurosurgery, Free University Hospital Amsterdam, 
The Netherlands) was induced by N-methylnitrosurea in Fischer 344 rats 
and characterised by Weizsaecker et al.(42). The U25I, D384 and LW5 
human glioma cell line (27,35) were obtained from Dr. C.H. Langeveld 
(Dept. of Pharmacology, Free University Hospital Amsterdam, The 
Netherlands). The A549 human lung carcinoma cell line (13) was pur-
chased from Biowhittaker (Brussels, Belgium). The GLC-I human small 
cell lung cancer (SCLC) cell line (lOa) was kindly provided by Prof. Dr. 
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L de Ley (Dept. of Clin. Immunology, State University Groningen, The 
Netherlands) and the 518 A2 human melanoma cell line (35) by Dr. P 
Schrier (Dept. of Clin. Oncology Academic Hospital, Leiden, The Neth-
erlands). 
Tumor cells were cultured in Dulbecco's modified Eagle's medium (9L, 
U251, A549, 518 A2)(Gibco) or RPMI 1640 (GLC-l) (Gibco) supple-
mented with penicilline (100 IU; Gibco), streptomycine (50 mg/ml; 
Gibco), 10% fetal calf serum and non-essential amino acids. GLC-l was 
cultured in RPMI 1640 (Gibco). The cells were grown at 37°C; 5% CO, 
in 80 or 175cm' flasks (Nunclon). 
Tumor cell doubling time 
To determine the doubling time of human glioblastoma cells in vitro, 
U251, D384 and LW5 tumor cells were plated in 24 well culture dishes 
(Costar) at a density of 10' cells/well. Every 24 hours for 6 days, quadru-
plet wells were trypsinised and living cells were counted by trypan blue 
exclusion method. Doubling time of the tumor cells were determined by 
the following formula; n= In (P/x)/In 2 (14,34); where n= number of cell 
divisions; p=number of cells after n divisions; x = initial number of cells, 
assuming that no cells are lost. Tumor cell doubling time was assessed by 
dividing the duration of the experiment (=6 days =144 hours) by the 
number of cell divisions. Statistical analysis (Student-t test) was per-
formed on the data to determine the significance of the observed differ-
ences in doubling time. 
Efficiency of gelle trallsfer in vitro 
The rat glioma and human tumor cells were plated in 24 well culture 
dishes (Costar) at a density of 10' cells/well. Cells in triplicate wells were 
infected with IG.Ad.MLP.LacZ or IG.Ad.CMV.LacZ at multiplicity of 
infections (m.o.i.) of 0, 10 or 100. To asess J3-galactosidase activity, tripli-
cate wells infected with LacZ-adenovirus were stained with X-Gal" sev-
enty-two hours after infection and examined microscopically. 
Killing efficiellCY in vitro 
Killing efficiency of GCV after TK-gene transfer was tested as described 
before (39,40). The rat glioma and human tumor cells were plated in 24 
well culture dishes (Costar) at a density of 10' cells/well and infected with 
IG.Ad.MLP.TK or IG.Ad.CMV.TK at m.o.i. 0, 10, 100 and 1000. 
Twenty-four hours later, the infected cells were treated with GCV 
(Syntex) at a concentration of 10 flg/ml or PBS (control). 48 hours after 
GCV administration, the cells were trypsinised and living cells were 
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counted by trypan blue exclusion method. Statistical analysis (Student t-
test) was perfonned on the data to answer the following questions: I. Are 
TKlGCV treated tumor cells killed more effectively than TKlPBS 
(controls) treated cells? 2. Is killing efficiency using the GCVrrK mecha-
nism in human tumor cells dependent on the promoter used (CMV versus 
MLP)? 3. Is TKlGCV tumor cell killing efficiency dependent on doubling 
time of human glioma cells in vitro? 
In vivo studies: 
Brain tumor 
Fischer rats (n=90) weighing between 250-350 grams were anesthetized 
with ether and placed in a stereotactic frame. A burr hole was made 1 mm 
in front of the bregma and 2 mm lateral of the midline. Consequently 
4xl0' 9L rat gliosarcoma cells in 1 JlI of Hank's buffered saline were in-
jected by a microliter syringe in the left forebrain, at a depth of 4 mm. 
The cells were injected over a period of 2 min. The needle was slowly 
retracted and the burr hole was closed with bonewax (Braun). The skin 
was closed with 9-mm clips. The same procedure and coordinates were 
subsequently used to inject recombinant virus; A volume of 10 JlI was 
infused over 5 min. along the needletract (1 JlI per 0.5 mm) starting 1 mm 
deeper than the injected tumor cells. Three days after tumor cell implan-
tation, rats were randomised, different amounts of IG.Ad.MLP.TK or 
IG.Ad.CMV.TK or PBS as a control were injected into the tumor in dif-
ferent groups: 1.10' (n=15), 1.10' (n=10), 1.10' (n=10) IU IG.Ad.MLP.-
TK, 1.10' (n=15), 1.10' (n=10), 1.10' (0=10) IU IG.Ad.CMV.TK and 
10 JlI PBS (n=20). Forty-eight hours after the injection of the virus, rats 
injected with either IG.Ad.MLP.TK, IG.Ad.CMV.TK or phosphate 
buffered saline (PBS) received twice a day intraperitoneal injections of 
GCV (15 mg/kg, Syntex, n=15) or PBS (n=30) for 10 days. Rats were 
observed daily and killed instantly when moribund or when neurological 
symptoms developed. Survival data of the rats were presented as Kaplan-
Meier" plots. The log rank test was applied for statistical analysis of sur-
vival data. 
Leptomeningeal metastases 
A modified 9L gliosarcoma model of leptomeningeal neoplasia was used 
as described earlier by Vincent et aI., (39). Briefly, male Fischer 344 rats 
(n=70) weighing 250-300 grams were anesthetized with ether, shaved 
suboccipitally and placed in a stereotactic frame with the skull in flexion. 
Consequently, 4xl0' 9L tumor cells in a volume of 30 ftl using a 0.1 ml 
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syringe were injected directly into the CSF of the cisterna magna. After 3 
days, rats were randomised and injected via the same route with; 2.10' IU 
IG.Ad.MLP.TK (n=2S), 2.10' IV IG.Ad.CMV.TK (n=2S) or phosphate 
buffered saline (PBS, n=20, control) in a volume of 30 ~ll. Rats injected 
with either IG.Ad.MLP.TK, IG.Ad.CMV.TK or phosphate buffered 
saline (PBS) received twice a day intraperitoneal injections of GCV (1S 
mg/kg, Syntex, n= IS) or PBS (n=30) for 10 days. Rats were observed 
daily and killed instantly when moribund or when neurological symptoms 
such as paralysis of the legs, unsteady gait or incontinence developed. 40 
The symptom free period of every rat was calculated starting with the 
injection of tumor cells on day O. The symptom free latency of each group 
was presented in a Kaplan-Meier plot (16). The log rank test was applied 
for statistical analysis of symptom free latency data. 
Results 
In vitro experiments: 
Tumor cell doubling time of human glioma cells 
Population doubling time of the different tumor cells differed significantly 
between the glioblastoma tumor cell lines used. (U2Sl vs D3841 U2SI vs 
LW51 D384 vs LWS: day I: ns/*I*, day 2: **1**1*, day 3: *1**1*, day 4: 
***1***1**, day S: ***1***1**, day 6: **I***I***)(Student t- test;*= 
p<O.OS, **=p<O.OI, ***=p<O.OOI, ns=not significant) (Fig.2). The mi-
totically most active tumor cell was U2SI with a mean doubling time of 
34.4 hours. The calculated tumor cell mean doubling times in D384 and 
LWS were 41.6 and 67.6 hours respectively(Fig.2 - appendix). 
LacZ expression 
Adenovirus mediated LacZ gene transfer to tumor cells was determined 
by X-Gal staining of the cells. LacZ activity could be microscopically de-
tected in the nucleus (nuclear localisation signal)of all tumor cells infected 
with IG.Ad.MLP.LacZ or IG.Ad.CMV.LacZ (Fig.3 - appendix). Con-
trols were negative for LacZ activity (data not shown). 
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Tumor cell division activity and doubling time of human glioblastoma cells. U251, D384 and 
lWS glioblastoma tumor cells were plated in 24 well culture dishes (Costar) at a density of 104 
cells/well. Every 24 hours for 6 days, quadruplet wells were trypsinised and viable cells were 
counted by trypan blue exclusion method, Tumor cell doubling was determined as described in 
Materials an Methods. (see also Table 1.) 
Killing efficiency 
All cultured tumor cells infected with IG.Ad.MLP.TK or IG.Ad. 
CMV. TK were sensitive to a killing effect after treatment with GCV 
within 72 hours (Fig.4). Human tumor cells treated with TKlGCV were 
killed significantly at higher percentages than cells treated with TKlPBS 
(controls) (MLP-promoter: moi 10: U251**, D384*, LW5*, GLC-Ol**, 
A549*, 518 A2***, 9L M, moilOO: U251 **, D384*, LW5*, GLC-Ol*, 
A549**, 518 A2**, 9L*, moi 1000: U251**, D384**, LW5**, GLC-
01 M , A549M, 518 A2**, 9L*; CMV-promoter: moi 10: U251**, D384**, 
LW5*, GLC-Ol*, A549***, 518 A2*, 9LM, moilOO: U251**, D384**, 
LW5*, GLC-Ol*, A549**, 518 A2***, 9L**, moi 1000: U251**, 
D384**, LW5*, GIC-OIM, A549**, 518 A2**, 9L**)(Student t-
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test;*=p<0.05, **=p<O.Ol, ***=p<O.OOl, ns=not significant). The tumor 
cell kill was also dependent on m.o.i. (Fig.4). However, human tumor 
cells infected at high m.o.i., also showed also cell death without GCV 
administration. Rapidly dividing tumor cells were killed at a significantly 
higher rate by TKlGCV treatment than slower dividing cells (U251 vs 
D3841 U251 vs D3841 D384 vs LW5: MLP-promoter: moi 10: *1**/ns, 
moi 100: *1***1**, moi 1000: ns/*I*; CMV-promoter: moi 10: **I*/ns, moi 
100: ns/***/ns, moi 1000: **/ns/ns)(Student t-test;*=p<0.05, **=p<O.Ol, 
***=p<O.OOl, ns=not significant), suggesting a correlation between divi-
sion rates of human glioblastoma cells and tumor cell killing efficiency. 
(Fig. 2,4). 
Mlp versus cmv promoter 
Tumor cells infected with IG.Ad.CMV.LacZ showed enlargement of cells 
and nucleus/plasma ratio was increased (Fig.3 - appendix) as compared to 
the IG.Ad.MLP.LacZ, suggesting toxicity. 
Most cell lines were killed more significantly after infection with adenovi-
rus-TK containing the CMV-promoter as compared to the adenoviruses 
containing the MLP-promoter (Fig.4)(moi 10: U251*, D384*, LW5**, 
518A2**, moi 100: U251*, D384*, LW5***, 518 A2*, moi 1000: 
U251**, D384*, LW5*, 518 A2**). No differences were found in the 
A549 and GLC-01 cells, although the GLC-01 cells* were killed more 
effectively at moi 100 with the MLP-vector. IG.Ad.CMV.TK was more 
toxic than IG.Ad.MLP.TK to U251, D384 and LW5 infected cells with-
out GCV treatment (Fig.4).(moi 10: U251*, moi 100: U251**, moi 1000 
U251 **, D384**,LW5**)(Student t-test;*=p<0.05, **=p<O.Ol, ***= 
p<O.OOl, ns=not significant). 
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Survival of tumor cells ( U251 human glioma cells, D384 human glioma cells, LW5 human 
glioma cells, GLC-01 human small cell lung carcinoma cells, A549 human non-small cell lung 
carcinoma cells, 518 A2 human melanoma cells and 9L rat glioma cells) that were infected in 
vitro with IG.Ad.MLP.TK or IG.Ad.CMV.TK and subsequently treated with GCV or PBS. Tumor 
• cells were plated at a density of lxl0 cells/well and infected at m.o.i. 10, 100 and 1000. 
Twenty-four hours later the cells were treated with GCV at a concentration of 1 0 ~Iglml or with 
PBS. After 72 hours the cells were trypsinised and surviving cells counted by trypan blue exclu-
sion method. The figure depicts the percentage of surviving tumor cells as a function of m.o.i.. 
Open bars: treatment with GCV. filled bars: treatment with PBS. 1. A. IG.Ad.MLP.TK B. 
IG.Ad.CMV.TK. 
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In vivo experiments: 
Rat brain tumor 
Injection of brain tumor with IG.Ad.MLP.TK or IG.Ad.CMV.TK did 
not show any clinical or neurological signs related to vector administra-
tion. Treatment with both viruses significantly prolonged survival after 
GCV administration as compared to control rats given PBS instead of 
GCV (Fig.S). Control rats had a median survival (days) of 18.0±1.0 SD 
(PBSIPBS), 17.0±1.7 SD (PBS/GCV), 16.0±1.3 SD (IG.Ad.MLP.TKI 
PBS) and 17.0±l.S SD (IG.Ad.CMV.TKlPBS) whereas IG.Ad.MLP. 
TKlGCV treated rats had median survival (days) of2S.0±9.2 SD (10' IU 
IG.Ad.MLP.TKlGCV), 19.0±1.7 SD (10' IU IG.Ad.MLP.TK/GCV), 
16.5±0.7 SD (10' IU IG.Ad.MLP.TKlGCV). One animal treated with 
10' IU IG.Ad.MLP.TKlGCV who had a survival time of 40 days, died of 
a superficial growing tumor that was caused by spill of tumor cells 
through the burr hole. No intracerebral brain tumor was present. 
IG.Ad.CMV.TK treated rats had a median survival (days) of 48.0±9.5 
SD (10' IU IG.Ad.CMV.TKlGCV), SO.0±8.S SD (10' IU IG.Ad.CMV. 
TKlGCV) and 2S.0±13.3 SD (10' IU IG.Ad.CMV.TKlGCV). The data 
thus clearly show; 1) a dose dependent survival for both vectors, 2) a bet-
ter therapeutic response after administration ofIG.Ad.CMV.TK as com-
pared to IG.Ad.MLP.TK, 3) that low doses ofIG.Ad.MLP.TK (10' IU, 
10' IU) are not effective anymore and 4) that administration of 107 and 
108 IU ofIG.Ad.CMV.TK had similar therapeutic effects, indicating that 
the maximal dose for single treatment was reached. 
Rat leptomeningeal metastases 
Similar to our findings in rats treated for brain tumors, animals treated by 
injecting the virus suboccipitally into the CSF showed no clinical or neu-
rological signs related to vector administration. Administration of both 
vectors followed by GCV treatment resulted in a significant prolongation 
of the symptom free period as compared to conu'ol rats (Fig. 6). Control 
rats had a median symptom free period (days) of 18±0.9 SD SD 
(PBSIPBS), 19.5±1.3 SD (PBS/GCV+), 18.0±1.4 SD (IG.Ad.MLP.TKI 
PBS) and 18.S±1.4 SD (IG.Ad.CMV.TKlPBS). Treated rats had median 
symptom free period (days) of 22.0±2.1 (IG.Ad.MLP.TKlGCV) and 
29.0±S.4 (IG.Ad.CMV.TKlGCV). Treatment with IG.Ad.CMV.TKI 
GCV caused a longer symptom free period as compared to IG.Ad.MLP. 
TKlGCV. 
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and subsequent GCV administration. Rats (n=90) were injected intracerebrally with 4xl0 9l 
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tumor cells. After 3 days, rats were injected via the same route with 106, 107 and 108 IU of 
IG.Ad.MlP.TK or IG.Ad.CMV.TK. Controls were treated with PBS. Twenty-four hours after tumor 
cell injection 15 mg/kg GCV or 1 ml PBS was administered Lp. twice a day for ten days. Survival 
time of rats was assessed. 
A Rats treated with 108 IU IGAd,MLP.TK and subsequent GCV lived significantly longer 
(p<O.OOl, respectively, log rank test) than control groups (PBSIPBS, PBS/GCV and IG.Ad.MLP. 
TKfPBS). Control groups were not significantly different from each other (p>O.ot). One animal 
treated with IG.Ad.MLP./GCV who had a survival time of 40 days, died of a superficial growing 
tumor which was caused by spill of tumor cells through the burr hole. No intracerebral brain 
tumor was present (*). (This rat is censored in the survival analysis). 
B. Rats treated with 108, 107 and 106 IU of IG.Ad.CMV.TK and subsequent GCV lived signifi-
cantly longer (p<O.OOl, p<O.OOl, p<O.Ol, respectively, log rank test) than all control groups 
(PBS/PBS, PBS/GCV and IG.Ad.CMV.TKlPBS). Control groups were not significantly different 
from each other (p>O.Ol).Additionally, rats treated with IG.Ad.CMV.TKlGCV lived signifi-
cantly longer than rats treated with IG.Ad.MlP.TKlGCV.(108 IU ip<O.Ol, 107 IU iP<O.OOl, 
106 IU ip<O.Ol, respectively, log rank test). 
Figure 6 
Kaplan-Meier curves of rats with established lepto-meningeal tumors treated with recombinant 
adenovirus and subsequent GCV administration. Rats (n=70) were injected intrathecally with 
4xl04 9l tumor cells. After 3 days, rats were injected via the same route with 2.109 IU 
IG.Ad.MLP.TK, IG.Ad.CMV.TK. Controls were treated with PBS. Twenty-four hours after tumor 
cell injection 15 mg/kg GCV or 1 ml PBS was administered i.p. twice a day for ten days. Rats 
were killed instantly when moribund or if neurological symptoms developed. Symptom free 
latency of every rat was assessed. 
Rats treated with (A) IG.Ad.MlP_TK or (8) IG.Ad.CMV.TK and subsequent GCV had significantly 
longer (p<O.OOl, p< 0.001, respectively, log rank test) symptom free latency than all control 
groups (PBSIPBS, PBS/GCV and IG.Ad.MlP_TKlPBS or IG.Ad.CMV.TK). Control groups were not 
Significantly different from each other (p>O.Ol). 
Additionally, rats treated with IG.Ad.CMV.TKlGCV had significantly longer symptom free period 
than rats treated with IG.Ad.MlP_TKlGCV.(p<O.01, log rank test). 
Preditlical testing of recombinant adenoviral HSV-tk gene therapy 
A. 
100 
j!J 
~ 15 ~ 
~ 
~ 
<!: 
§ 50 
'" a 
... 
~ 25 
tI' 
10 15 20 25 30 35 40 
days 
B. 
100 
j!J 
~ 15 ~ 
'" 
'" <!: 
S so 
S 
'" S 
i;! 
" 
"" 
0 
I' 15 20 
" 
30 35 40 
days 
PBS/PBS 
PBS/GCV 
103 
2.10'JU JG.Ad.MLP.TKlPBS 
2.1O'JU JG.Ad.MLP.TKlGCV 
PBS/PBS 
PBS/GCV 
2.1O'JU JG.Ad.CMV.TKlPBS 
2.1O'JU JG.Ad.CMV.TKlGCV 
104 Chapter 5 
Discussion 
In this study we demonstrate a high efficiency of recombinant adenovirus 
mediated gene transfer to several human glioblastoma cell lines and cells 
derived from cancers known to metastasise to the CNS (Fig.3). The data 
also show that tumor cell kill after adeno-TKlGCV treatment was very 
efficient in all human tumor cell lines tested (Fig,4). A few investigators 
have reported a killing effect of adeno-tklGCV treatment in several rodent 
brain tumor cell lines (10,27,40) in vitro and ill vivo. We demonstrate that 
clinically important primary and secondary human CNS tumors can be 
efficiently transduced by adenoviral vectors and killed effectively by the 
TKlGCV treatment. 
Tumor cell kill effectivity varied between the different human tumor cell 
lines (Fig.4). Unexplained variations of recombinant adenovirus trans-
duction of different tumor cell lines have been described by others as well 
(4,13a). We have no satisfactory explanation for this phenomenon, but is 
most likely caused by differences in the numbers of receptors (37) and/or 
integrins (15,45,46) needed for attachment and internalisation of the ade-
novirus, respectively. 
Additionally, our study suggests that killing efficiency in glioblastoma 
tumor cells correlate with cell doubling time (Fig.2, 4). The data show 
that mitotically active tumor cells (U251) are more effectively killed by the 
TKlGCV treatment than less actively dividing tumor cells (D384,LW5). 
This observation could be explained as follows; as the TKlGCV mecha-
nism interferes with DNA synthesis, cell populations containing a rela-
tively large fraction of 'S-phase' cells will be more sensitive than 
mitotocally less active cells. Our data suggest that tumor cell doubling 
time is an important parameters in the TKlGCV cell killing mechanism 
(10). 
Adenoviral vectors harbouring different promoters have been developed 
by several investigators (2,5,10,27,40). Wills et al.(46) showed that the 
CMV promoter expressed higher levels of the p53 protein and demon-
strated a significant stronger effect in vitro as compared to the MLP pro-
moter. In our experiments, the majority of human tumor cells infected 
with the vector containing the CMV promoter showed significantly 
stronger anti-tumor effect in vitro and in vivo than the MLP promoter 
vectors. However, not all human cells showed higher cell kill with the 
CMV promoter (Fig.4). Higher expression and killing efficiency of the 
GLC-1 small cell lung cancer cells after adenovirus infection harbouring 
the MLP promoter was observed. We have no satisfactory explanation for 
this intercellular variation of promoter preference but it could be an im-
Preclim'cal testing of recombillant adenoviral HSV-tk gene therapy 105 
portant issue when clinical use of recombinant adenovirus is considered. 
Whether MLP or CMV constructs should be used in clinical studies de-
pends on the balance between effectivity of tumor treatment and toxicity 
of the vectors to nonnal tissues. 
Wills et al.(46) did not report on differences in toxicity of the vectors. In 
this study however, cytotoxicity in some human cells infected in vitro with 
IG.Ad.CMV.TK was significantly higher than with IG.Ad.MLP.TK 
(Fig.4). Cytopathic effects were also observed in IG.Ad.CMV.LacZ in-
fected cells (Fig.3) suggesting that toxicity is caused either by overexpres-
sion of the trans gene or by the CMV promoter itself. This is in line with 
the observation that tumor cells infected at high m.o.i. with 
IG.Ad.MLP.TK without GCV treatment resulted also in toxiciry (Fig.4). 
Another explanation for cytotoxicity in cells infected with recombinant 
virus containing the CMV promoter could be an excessive binding of 
transcription factors to the CMV promoter leading to cell death. 
Effectivity ofa single treatment with IG.Ad.MLP.TK or IG.AdCMV.TK 
and subsequent GCV administration in experimental brain tumors and 
leptomeningeal metastases is demonstrated in this study (Fig.5,6). The 
data show that the therapeutic effect is dose dependent, saturable, caused 
by the TKlGCV mechanism, and not directly related to a viral induced 
immune reaction (survival or sytnptom free period was not increased in 
rats treated with IG.Ad.TKlPBS ). In line with our observations in vitro 
in the 9L cell line, the CMV promoter containing vectors were signifi-
cantly more effective than the MLP constructs. As almost no toxicity of 
the CMV vectors to rat 9L cells was observed (Fig.4), these data can be 
explained only by the higher levels of gene expression by the CMV con-
taining vectors as compared to MLP. Our data underscore the importance 
of adenovirus vectors for in vivo HSV-TKgene delivery. 
None of the animals injected with the recombinant adenovirus in this 
study showed any neurological or other clinical signs related to the vector 
and/or GCV administration demonstrating the clinical feasibility of this 
approach. Since human tumor cells are more effectively killed than the 9L 
rat brain tumor cells (Fig.4), an even stronger therapeutic effect may be 
expected in a clinical situation. Additionally, larger volumes can be ad-
ministered intratumorally or intrathecally as compared to the limited in-
jection volume in rats. The data in this study also show that recombinant 
adenovirus can be transported within the CSF flow to kill leptomeningeal 
tumor cells effectively and is not immediately inactivated by humoral or 
cellular factors. 
Several recombinant viruses have been described as vectors for HSV-tk 
gene delivery to tumor cells (6,8,lO,IOb,1l,25,27,31). Retrovirus-TK 
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producing cells have shown to prolong survival of rats carrying experi-
mental brain tumor or leptomeningeal neoplasia after GCV administra-
tion (11,25,31). However, only low virus titers can be achieved and the 
use of murine vector producing cells do have volume and immunological 
constraints in a clinical situation. Intrathecal injection of producer cells 
may also induce CSF pathway obstruction problems. Retroviral vectors 
will only integrate into the genome of dividing cells which can be a disad-
vantage, since the majority of cells in human malignant brain tumors re-
main in GO phase (23,47). Clinical studies using murine fibroblasts 
producing HSV -tk retroviral vectors in patients with recurrent glioblas-
toma have been shown to induce some tumor regression but prolonged 
survival has not been reported yet (30). Transduction efficiency of tumor 
cells was very low in this study and seizures, severe headache, pancy-
topenia and meningeal inflammation have been noted during treatment. A 
phase 1 clinical trial for the treatment of leptomeningeal neoplasia using 
the same producer cells was closed temporarily after transient meningeal 
inflammation (32a). Immunogenic properties of the producer cells are 
most probably responsible for these side effects. Recombinant Herpes 
Simplex vectors which have the advantage to replicate in dividing cells but 
not in non-dividing cells, have also been proven to be effective in treating 
experimental brain tumors (7,9). However, the high immunogenic and 
toxic properties of the virus are major problems that need to be overcome 
before application. Adenovirus has the advantage that high titers can be 
obtained and that cell-free virus can be injected directly into the tumor. 
Both dividing and non- dividing cells are infected by the vector and inser-
tional mutagenesis is unlikely because adenovirus does not integrate into 
the genome. Disadvantages however, could be the immunological and 
toxic constraints. Although immunological toxicity was not specifically 
addressed in this study, we previously demonstrated that no morphologi-
cal changes or cytopathic effects were observed in the CNS of rats injected 
intratumorally or intrathecally with IG.Ad.MLP.TK (39,40). It is still a 
matter of debate whether significant immune responses occur in the rela-
tively "immune privileged" CNS after single or multiple injections of re-
combinant adenovirus (7,10,27,37,40). Although immune responses have 
been described after instillation in several organs (5), our group (unpubli-
shed data) found no clinical toxicity in CNS of rodents after intracerebral 
or intrathecal injection of recombinant adenovirus. A possible explanation 
could be that in contrast to others, we retained the E3 region in our ade-
noviral constructs, which is responsible for evading host's immune re-
sponse by down regulating MHC 1 expression in transduced cells (17). 
Based on the data described in this paper we consider clinical studies for 
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malignant glioma and leptomeningeal metastases aimed at assessing effi-
cacy and toxicity of the TKlGCV treatment. 
Conclusions 
Gene expression in, and killing efficiency of human CNS tumors can be 
efficiently achieved with adenoviral vectors in vitro and in vivo. Our data 
also show the therapeutic effectivity and feasibility of treatment of experi-
mental rat brain tumors and leptomeningeal metastases with recombinant 
adenovirus harbouring the HSV-tk gene and GCV. 
Infection with recombinant adenovirus containing the CMV promoter 
showed higher GCV mediated killing efficiency in most human tumor 
cells tested than with adenovirus harbouring the MLP promoter. Infection 
by recombinant adenovirus harbouring the CMV promoter was however, 
also accompanied by cytotoxicity. 
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Abstract 
HSV-tk gene transfer into tumor cells followed by Ganciclovir (GCY) admini-
stration is a promising approach for the treatment of central nervous system 
malignancies, since specifically mitotic cells are destroyed while surrounding 
brain tissue is spared. In this study, we investigated clinical signs or symptoms 
and histopathology of brain tissue after intracerebral injection of recombinant 
adenovirus containing the HSV-tk gene in rats followed by systemic GCVad-
ministration. Furthennore, systemic involvement and spread of the virus 
through the CNS was studied. Rats were injected in the left frontal lobe with 10' 
or 10' Infectious Units (IU) of IG.Ad.MLPI. TK, PBS (controls) or wild-type 
adenovirus followed by GCV or PBS for 16 days after which they were killed 
and histopathological examination of the brain was peifonned. No clinical ad-
verse reaction was observed in any of the treated animals. After administration 
of 10' IU of IG.Ad.MLPI. TK histopathological examination revealed mild to 
moderate perivascular infiltration in the near vicinity of the injection site. Ani-
mals injected with 10' IU IG.Ad.MLPI. TK showed moderate to severe perivas-
cular lymphoid infiltration, glial proliferation, edema and parenchymal loss 
extending to basal and baso-lateral area of the frontal lobe and also caudally, 
but generally not exceeding a distance of 2-3 mm from the injection canal. An 
additional effect of GCV administration was not observed. Rats injected with 
wild-type adenovirus showed more severe lesions compared to those treated with 
10' IU IG.Ad.MLPI. TK, which could have been induced by proteins tran-
scribed from the preserved E1 region. In this rat study, we demonstrate that 
intracerebrally injected recombinant adenovirus harbouring the HSV-tk gene 
causes dose dependent, but rather limited brain lesions not associated with short 
tenn major functional disturbances. In another exp .. iment, rats were injected 
intracerebrally with IG.Ad.MLP. LacZ (containg the LacZ gene) or IG.Ad. 
MLP.luc (containing the luciferase gene) to study intracerebral and systemic 
spread of the virus, respectively. LacZ expression was observed at some distance 
and in the contralateral hemisphere of the injection site. However, no luciferase 
activity was measured outside the CNS. 
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Introduction 
Most malignancies of the central nervous system are still devastating tu-
mors with poor prognosis despite aggressive surgery, chemotherapy and 
radiotherapy (1-3). Transfer of the Herpes Simplex Virus thymidine 
kinase (HSV -tk) gene into brain tumor cells followed by Ganciclovir 
(GCV) administration is a newly developed experimental cancer therapy 
(4-9). Expression of the HSV-tk gene renders dividing cells sensitive to 
GCV(10). Since the HSV-tklGCV mechanism specifically kills mitotic 
cells, central nervous system tumors which are embedded in non-dividing 
tissue are ideal candidates for this approach. Several investigators have 
shown the efficacy in vitro and in vivo and clinical trials are in progress. 
Recombinant retrovirus (4, 5, 11), Herpes Simplex virus (12, 13) and 
adenovirus (8, 14, 15) have been used as vectors to deliver the HSV-tk 
gene to the tumor cells in vivo. Recombinant adenoviral vectors have sev-
eral advantages; they are stable, cell free virus can be administered directly 
in vivo and high titers can be obtained. They can infect a broad range of 
dividing and non-dividing cells very effectively and insertional mutagene-
sis is unlikely because the DNA is not integrated into the host cell 
genome. Recombinant adenoviral vectors used for most gene therapy 
studies, including the studies reported here, are derived from the sub-
group C adenoviruses types 2 and 5 which are known to induce self lim-
iting mild respiratory tract infections. The vector seems therefore an ideal 
candidate to be used for treating brain tumors. However, although the 
brain is regarded as an immune protected site, several sero-types of ade-
novirus have been shown to cause encephalitis in newborn infants, im-
mune deficient humans and also occasionally in adults (16-31). Another 
limitation in the use of these vectors could be the pre-existing immunity to 
adenoviruses type 2 and 5 in the general popUlation. Repeated injections 
could lead to direct complement mediated inactivation after two or more 
administrations (32). 
Delivery of the adenoviral vectors to brain tumors has been achieved in 
experimental animals by either direct intra-tumoral injection or intra-
arterial administration followed by osmotic disruption of the blood brain 
barrier (8, 14, 15,33-35). In one clinical trial the vector is installed into 
the ''tumor bed" after glioma resection to prevent regrowth of the tumor 
(36). Application of the vector in either way will also transduce healthy 
non-dividing brain tissue. Since the vector has also potency to be used in 
replacement therapy for neurodegenerative diseases and neural regenera-
tion therapies, cytotoxicity of the vector on brain tissue is a very important 
issue to address. Previous studies showed that neurons, glial cells, choroid 
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plexus and ependymal cells can be transduced by recombinant adenoviral 
vectors without significant toxicity (37-42). Others, however, observed 
dose dependent intracerebral inflammatory responses after vector instilla-
tion in rats or primates (32, 36, 40, 43, 44). 
We investigated the histopathology in the rat brain after intracerebral 
injection of adenoviral vectors harbouring the HSV-tk gene and subse-
quent GCV administration. Furthermore, the spread of the virus to other 
organs after intracerebral injection was investigated in rats. 
Methods en materials 
Adenoviral Vectol's 
IG.Ad. MLPLTK is derived from IG.Ad.MLP.TK as will be described 
elsewhere (44a). IG.Ad.MLPLTK is similar to IG.Ad.MLP.TK (delta E1 
459-3328) except that the El deletion in the vector is extended (delta 
459-3510) and non-coding LacZ sequences present in IG.Ad.MLP.TK 
are deleted. The E3 region is contained in this construct. Similar adenovi-
ral vector constructs containing the firefly luciferase (luc) or nls-LacZ 
genes (Escherichia coli LacZ gene preceeded by the SV40 large-T nuclear 
localisation signal) were made. The luc complementary (c) DNA was de-
rived from pRSV.luc (45). Generation of these adenoviral vectors is de-
scribed elsewhere (6). 
Recombinant viruses were generated by co-transfecting 293 cells with Sal 
I linearized pMLP.TK or pMLP.luc and the large Cia I fragment of wild-
type Ad5 DNA. Recombinant viruses were plaque purified twice, propa-
gated, and titrated according to standard procedures (47). Virus titers 
determined by endpoint titration ranged from 1010 to 1 011 IU/ml. The re-
spective resulting recombinant viruses were named IG.Ad.MLPLTK and 
IG.Ad.MLP.luc. A map of the recombinant adenoviral vectors used is 
depicted in figure 1. The wild-type adenovirus subtype 5 was obtained 
from Prof.Dr.P.C. van der Vliet (Universtiy Hospital Utrecht). 
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Figure 1 
Map of the constructed recombinant adenoviral vectors. Shown is the Human Ad 5 DNA con-
taining the expression cassette. The cassette (enlarged) contains the Adenovirus type 2 major late 
promoter (MlPI). The promoter is preceded by an inverted terminal repeat, {ollowed by either the 
nlsLaeZ, (Escherischia coli LacZ gene preceded by the nuclear localisation signa!), Herpes Sim-
plex derived Thymidine Kinase (TK) suicide gene or luciferase (iuc.) gene. Transcription is termi-
nated by SV40 poly-adenylation sequences. 
Prom.: MlP promoter. Transgene: either TK, nlsLaeZ gene or luc. gene. 
Ad 5: human adenovirus DNA. IlR: inverted terminal repeat. p(A): SV4Q poly-adenylation se-
quences. 
Experimental procedures 
Intracerebral injection of IG.Ad.MLPI. TK 
Fischer rats weighing 150-200 grams were anaesthetized and placed into a 
stereotactic device. A burr hole was made I mm in front of the bregma and 
2mm off the midline. The rats were injected inu'acerebrally with 108 (11l1) 
or 10' (101l1) IV IG.Ad.MLPI.TK, 108 (11l1) IV WtAd5 (\Vildtype ade-
novirus; subtype 5) or PBS via a microliter syringe into the left forebrain, 
at a depth of 4 mm. The needle was slowly retracted and the burr hole 
was closed with bone wax (Braun). The skin was closed with 9 mm clips. 
Twenty-four hours later the rats were treated twice daily for 14 days with 
either intraperitoneal injections of GCV (15mg/kg, Syntex) or PBS. The 
eight different groups were treated as follows: I) 108 IV IG.Ad.MLPI.TK 
(11l1)/GCV (n=3); 2) 108 IV IG.Ad.MLPI.TK (11l1)IPBS (n=3); 3) PBS 
(11l1)/GCV (n=2); 4) PBS (11l1)IPBS (n=2); 5)108 WtAd5 (lfll)IPBS 
(n=2); 6) 10' IV IG.Ad.MLPI.TK (IOIlI)/GCV (n=4); 7) 10' IG.Ad. 
MLPI.TK (IOIlI)IPBS (n=3); 8) PBS (IOIlI)/GCV (n=2). The animals 
were observed daily for any clinical signs or symptoms and killed 16 days 
after intracerebral injection. The rats were perfused via the left cardiac 
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ventricle with ice-cold 4% parafonnaldehyde. The brain was removed, 
and fixed in the same solution. The brains were cut transversely into 6 
sections: 1) just caudally of the injection site, 2) in front of the optic chi-
asm opticum, 3) through the caudal part of the mammillary body, 4) 
through the anterior part of the pons and 5) through the middle of pons 
and 6) cerebellum. The sections, numbered 1-6 from rostral to caudal 
were embedded in paraffin and cut from the rostral side (except the fron-
tal slice which was cut from the caudal side) into 4 11m slices. After stain-
ing with hematoxylin, phloxin and saffrane (HPS), the slices were 
examined microscopically. 
A semiquantitative grading system for estimating severity and expan-
sion of the lesion to areas at some distance of the injection site was ap-
plied. The severity (S) was scored in the most severely affected slice 
(generally slice nr. 1.) as 0, no lesions; 1, mild; 2, moderate; or 3, severe; 
depending on the presence and severity of perivascular lymphoid infiltra-
tion, gliosis, parenchymal loss and edema, and ventricular dilation. The 
extent (E) of the lesions was scored as: 1, injection canal only; 2, lesions 
within 0,5 mm from the margin of the injection canal; 3, lesions elsewhere 
in the frontal lobe but limited to the first slice only: 4, lesions also in the 
adjacent slice nr. 2; and 5, lesions also in slice nr. 2 and nr. 3. The total 
score for the reactive changes in each rat was determined by S x E. 
Intracerebral, suboccipital and intracardial injection of IG.Ad.MLP.luc 
Fischer rats (n=22) weighing 300 to 400 grams were anesthesized with 
ether. Rats were injected intracerebrally, suboccipitally or intracardially 
with either 10' ill IG.Ad.MLP.luc. or PBS (controls). The rats treated 
intracerebrally were treated by the same injection procedure as described 
above. A volume of 10111 containing 10' ill IG.Ad.MLP.luc. (n=3) or 
PBS was injected into the left forebrain. Rats treated suboccipitally were 
treated as described by Vincent at al (15). Briefly, rats were shaved suboc-
cipitally and placed in a stereotactic frame with the skull in flexion. 10' ill 
IG.Ad.MLP.luc. or PBS (controls) in a volume of 30111 using a 0.1 ml 
syringe was then injected directly into the CSF of the cisterna magna. The 
proper position of the needle tip was confirmed by CSF aspiration prior to 
injection. For intracardial administration, rats were shaved on the chest 
and injected directly into the left ventricle of the hart. The proper position 
of the needle tip was confirmed by aspiration of pulsating blood prior to 
injection. A volume of 30 III using a 0.1 ml syringe was used to inject 10' 
ill IG.Ad.MLP.luc. or PBS (controls) directly intracardially. The animals 
were observed daily for clinical signs or symptoms. Three or 14 days after 
injection, the rats were anesthetized with ether and perfused through the 
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left cardiac ventricle with ice cold PBS. The heart, lung, liver, spleen, 
gastrointestinal tract, kidney, gonads, brain and spinal cord were re-
o 
moved, snap-frozen and stored at -80 C. The frozen organs were placed 
in ice-cold 100mM potassium phosphate buffer pH 7.S. Subsequently the 
organs were disrupted with a tissue mincer and lysed by adding 0.1 % 
Triton X-lOC and ImM DTT. After centrifugation, luciferase activity 
was determined in 20 ~tl of the supernatant by measuring the integrated 
light emission with a luminometer for 10 seconds in the presence of 25 
mM adenosine triphosphate and 1 mM luciferin. 
Iml'acerebrai injection of IG.Ad.MLP.LacZ 
Fischer rats weighing 150-200 grams (n=3) were anesthetized and in-
jected with 10' IU IG.Ad.MLP.LacZ using the same procedure as de-
scribed above. The same injection procedure was used as described above. 
The rats were injected intracerebrally with 10' IG.Ad.MLP .LacZ. The 
animals were observed daily for any clinical signs or symptoms and killed 
3 days after injection. The rats were perfused under anesthesia via the left 
cardiac ventricle with ice-cold 4% paraformaldehyde, the brain was re-
moved, and fixed in the same solution. The brain was cut into 5 trans-
verse sections. Subsequently, the sections were cut with a vibratome into 
100 /Jm sections, washed thoroughly with PBS and stained with X-Gal for 
3 hours. The sections were then counterstained with hematoxylin/eosin 
and examined microscopically for reporter gene expression. 
Results 
Imracerebl'ai injection of IG.Ad.MLPI. TK 
Intracerebrally injected animals with recombinant or wild-type virus did 
not cause any clinical signs or symptoms. After sacrifice, all brains showed 
histological changes due to the injection procedure itself. These changes 
included mild edema, mild mononuclear cells infiltration, especially with 
macrophages, mild glial cell proliferation, reactive vascular changes and 
multinucleated giant cells in the meninges. These reactions were restricted 
to the direct vicinity of the needle track (Fig. 2A - app.). All rats treated 
with IG.Ad.MLPI.TK showed mild (Fig. 2B - app.) to severe lesions 
(Fig. 2C - app.). The more severe lesions were characterized by multifocal 
perivascular lymphoid cell infiltration and glial cell proliferation, severe 
edema, parenchymal loss and punctuate mineralisation (signs of acute cell 
death however were not observed). The lesions extended mostly along the 
outer edge of the capsula externa to the basal and baso-lateral area of the 
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frontal lobe and in some cases also caudally. Expansion to the more cau-
dally located structures (slides 2 and 3) generally was characterized by less 
severe lesions such as perivascular lymphoid infiltration and glial cell pro-
liferation focally in the nucleus caudatus and thalamus. In sporadic cases, 
lesions were observed also in the contra-lateral hemisphere (Fig. 2D 
app.). Ventricular dilatation was not uncommon in the most severely af-
fected rats. The results of the scores for severity, extension and total score 
of the lesions observed in the 8 groups injected intra cerebrally are pre-
sented in table I. It appears that 2 of the 6 rats treated with 10' IU 
IG.Ad.MLPI.TK. and 2 of the 2 rats treated with 10' IU WtAd5. showed 
mild lesions with total scores ranging from 1,5-4,5. In the high dose 
groups (10' IU) all IG.Ad.MLPI.TK treated rats showed moderate to 
severe lesions mostly limited to the first and second slice i.e. not outside 
2-3 mm from the injection site, resulting in total scores ranging from 
6-12,5. An effect of additional GCV treatment was not observed. 
Intracerebral, suboccipital or intracardial injection of IG.Ad.MLP.luc 
None of the injections caused clinical symptoms until 3 or 14 days after 
IG.Ad.MLP.luc injection. Luciferase activity was detected in the brains of 
rats treated intracerebrally, after 3 and 14 days, but not in any other or-
gans. Suboccipitally injected rats showed luciferase activity in spinal cord 
and brain after 3 and 14 days but not in any other organ. Several organs 
of the intracardially injected rats (positive controls) showed luciferase 
expression after 3 and 14 days. Activity was detected in heart, lung, liver 
spleen and kidney. After 14 days luciferase could still be detected in liver, 
spleen and kidney (Fig. 3). 
Figure 3 
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Mean luciferase activity after 3 or 14 days in brain, central cord, hart, lung, liver, pleen, gastro~ 
intestines, kidney and gonads after intracerebral (A), suboccipital (8) or intracardial (C) (positive 
control) injection of 108 IU IG.Ad.MlP.luc. Rats were injected intracerebrally, suboccipitally or 
intracardially with either lOs IU IG.Ad,MlP.luc. or PBS (controls). Three or 14 days after injec-
tion, the rats were killed and hart, lung, liver spleen, gastro-intestines, kidney, gonads, brain and 
spinal cord were removed. The organs were lysed and luciferase activity was determined, Activity 
is presented as light units per milligram of soluble protein (lU/mg). 
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revealed reporter gene expression along the injection track and along the 
meninges near the injection site (Fig 4A - app.). Transduced cells were 
observed along the border of the corpus callosum with nucleus caudarus 
and white matter in the direct vicinity of the injection track. However, 
transduced cells were also observed along the corpus callosum directly 
contralaterally of the injection track (Fig. 4B - app.). No transduced cells 
were observed in frontal thalamus, nucleus caudarus or cerebellum 
(results not shown). 
Discussion 
Rats treated intracerebrally with 10' IU IG.Ad.MLPLTK all showed 
moderate to severe brain lesions which were most pronounced in the vi-
cinity of the needle track and along the outer edge of the capsula externa. 
Lesions were only sporadically observed at distances further than 2-3 mm 
from the needle track and if so they were only mild. Dose reduction to 10' 
IU caused a sharp decrease in severity and extend of the lesions with 4 or 
6 rats, not different from the control rats. The dominant type of lesion is 
the perivascular lymphoid infiltration which suggests a T-cell mediated 
pathogenesis as described earlier for recombinant adenovirus lesions in 
lungs (48) and eNS (32,43). 
The sporadic focal lesions consisting of perivascular lymphoid infiltration 
and proliferation observed in the contralateral hemisphere may be due to 
viral spread via the subarachnoidal space (by leakage from the injection 
site) or by transport via intracerebral fluid movements, due to retrograde 
transport of the virus via the normal commisural connections. Although 
clear-cut necrosis or apoptotic cell death was not observed, rats treated 
with high dose IG.Ad.MLPI.TK showed areas of loosely textured ede-
matous brain tissue with decreased cellular density and multifocal punc-
ruate mineralisation. These phenomena and the associated ventricular 
dilatation indicate acute parenchymal loss (cells and white matter). The 
increase in reactive changes with high dose IG.Ad.MLPLTK suggest a 
recombinant adenovirus dose dependent inflammatory reaction. This 
could have some drawbacks in an evenrual clinical setting. However, the 
relative dose applied to the human brain would be several times smaller, 
as the virus is injected into the tumor or rumor bed and over a larger area 
than was the case in the rat brain, leading to a considerable dilution. 
Furthermore, tissue damage observed in this experiment is relatively small 
when compared to the damage inflicted by neurosurgical tumor resection 
or by postoperative irradiation and might therefore be regarded as an ac-
ceptable side effect. In addition, it is reasonable to assume that the in-
flammatory response can partially be suppressed in humans by the use of 
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preoperative corticosteroids. Although investigators have suggested in-
creased toxicity of high dose TK virus when combined with GCV in nor-
mal brain tissue (49), IG.Ad.MLPI.TKlGCV treated rats in our 
experiment did not show differences in histopathology as compared to 
IG.Ad.MLPI.TKJPBS treated rats (Table 1). Other GCV dosages and 
animal species used could be an explanation for the observed differences. 
Theoretically, GCV administration is not expected to aggravate toxicity 
after recombinant HSV -TK containing adenovirus, since in non-dividing 
tissue the TKlGCV suicide mechanism is not expected to be active. 
Table 1 
Group Rat Nr. 
1 I 
2 
3 
2 4 
5 
6 
3 7 
8 
4 9 
10 
5 11 
12 
6 13 
14 
15 
16 
7 17 
18 
19 
8 20 
21 
Severity (S), extend (E) and total score (S x E) of reactive 
changes in rat brains 16 days after intracerebral injection of 
adenoviral vector 
Trealment Dose Volume Severity Extension Total Score 
(IU) Score Score 
IGAd.MlPI.TK+GCV 1.10' 1 III 1-2 3 4,5 , 
IG.Ad.MlPIoTK+GCV 1.10 1 ,Il 0-1 1 0.5 , 
IG.Ad.MlPI.TK+GCV 1.10 1 ,ll 0-1 1 0,5 
IG.Ad.MlPI.TK+PBS 1.10' 1 ~Il 0-1 1 0,5 , 
IG.Ad.MlPI.TK+PBS 1.10 1 "l 0-1 1 0,5 
IG,Ad,MlPI.TK+PBS 
, 
1.10 1 pl 0-1 3 1,5 
PBS+GCV - 1 pl 0 0 0 
PBS+GCV - 1 ,Il 0-1 1 0,5 
P8S+PBS - 1 ,ll 0-1 1 0,5 
PBS+PBS - 1 ,Il 0-1 1 0,5 
wtAdS+PBS 1.10 1 ,IL 1-2 3 4,5 
\vtAdS+PBS 
, 
1.10 1 ,Il 1-2 3-4 5.2 
IG.Ad,MlPI.TK+GCV 1.10 10Ill 2 3-4 7 
9 
IG.Ad.MlPI.TK+GCV 1.10 10lll 2-3 5 12,5 
9 
IG.Ad.MlPI.TK+GCV 1.10 10,ll 2 3 6 
9 
IG.Ad.MlPI.TK+GCV 1.10 10,ll 2 4 8 
IG.Ad.MlPI.TK+P8S 1.10 10,ll 2-3 4 10 
9 
IG.Ad,MlPI.TK+PBS 1.10 10,IL 2-3 5 12,5 
IG.Ad.MlPI.TK+PBS 1.10 
9 
10,ll 2-3 4 10 
PB5+GCV - WilL 0~1 1 0,5 
PBS+GCV - 10,ll 0 0 0 
Rats injected with wild-type adenovirus showed lesions indistinguishable 
from those due to IG.Ad.MLPI.TK at the same dose level, but slightly 
more severe and more extensive. We have no explanation for this obser-
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vation. Fischer rats are not known to be permissive or semi-pennissive for 
hwnan adenoviral type 5 infection. Proteins transcribed from the EIA 
region in the replication competent Ad5 could be responsible for the slight 
increase in neurotoxicity as compared to the EIA-deleted recombinant 
adenovirus. Unpublished data of our group showed no pathological effects 
of intracerebrally injected IG.Ad.MLPI.TK or wild-type Ad5 virus in the 
brain of Cotton rats, that are known to be semipennissive for the wild 
type virus in the lung (50). 
The luciferase experiment shows that intracerebral or SUboccipital injec-
tion of recombinant virus does not reveal detectable expression of the 
transgene in organs outside the CNS (Fig. 3). Although intracardially 
injected animals (positive controls) did show expression in several organs, 
vascular spread of the recombinant virus with subsequent trans gene ex-
pression outside the CNS after intracerebral or intrathecal injection was 
not detectable. These data contrast with the data from Goodman et aI., 
(49) who demonstrated spread of recombinant adenovirus-tk (in pri-
mates) using PCR detection, outside the nervous system (marrow, liver, 
lung). Transgene expression in these organs however, was not addressed 
in their study. In our study spread of recombinant virus within the CNS is 
demonstrated (Fig. 3, 4 A,B - appendix). Rats injected suboccipitally with 
adenovirus containing the luciferase gene demonstrated activity within 
brain and spinal cord tissue. This can be explained by transport via the 
CSF flow all along the CNS. Intracerebral injection, however, did not 
revealluciferase activity in the spinal cord, indicating that transport via the 
CSF contact is essential for spread throughout the CNS. We reported 
previously that recombinant adenovirus is transported vety effectively 
along the CNS after intrathecal delivety (6). No clinical signs of viral 
meningitis were observed in our study. The LacZ experiments shows in-
tracerebral spread of recombinant virus after injection into the brain. Al-
though trans gene expression was observed in the direct vicinity and at a 
distance of the injection site, some cells (neurons, glia cells) in the con-
tralateral hemisphere were also transduced (Fig. 4A,B - appendix). Fur-
thermore, spread of virus was restricted to anatomical borders within the 
brain (along corpus calloswn). \Vhether recombinant virus migrates or is 
transported to the nucleus retrogradally into the contralateral hemisphere 
after infection of the axon in the vicinity of the injection site is still a mat-
ter of debate. It has been demonstrated that single neurons in mice can 
transport recombinant virus via a retrograde axonal route over a large 
distance within or to the brain (51-53), which demonstrates that in-
tracerebrally injected virus particles has the potency to spread within the 
CNS. 
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Several investigators have studied recombinant adenoviral gene transfer 
into experimental rat brain tumors (6, 8, 14, 15, 33, 54, 55). Although 
several investigators have shown efficient CNS transduction by recombi-
nant adenovirus (35-40, 42, 44, 56, 57), only few have investigated the 
pathogenic effects of the infectious virus on healthy brain tissue (40, 43, 
44, 49). Byrnes et aI., 'demonstrated that injection of recombinant ade-
novirus-LacZ into the rat brain leads to an inflammatory response that 
gradually decreases within 2 months, although expression of the transgene 
was still evident at that time(32). The inflammation was initiated by the 
virions rather than through the expression of new proteins from the vec-
tor. In another experiment Byrnes et aI., 'showed that although adenoviral 
vectors can persist in the brain without causing chronic inflammation, 
they remain a potential target of a damaging cell-mediated immune re-
sponse after a second exposure to the vector. We did not address this spe-
cific issue in our experiments but it should be investigated before 
considering human trials in which repeated injections over time are con-
sidered. 
Toxicity studies in primates using recombinant adenoviral vectors have 
been conducted by only few investigators (40, 44, 49, 58). Toxicity stud-
ies in non-human primates showed only limited neurotoxicity. Goodman 
et aI., '(49) however, reported severe toxicity in baboon's brain after re-
combinant adenovirus -tk (containing the RSV promoter) and subsequent 
GCV administration. Animals treated with high dose recombinant ade-
novirus-tk (1.5xl0' IV) and GCV died or became moribund. Necropsies 
revealed necrosis at the injection sites. High dose adenovirus-TK without 
GCV administration and low dose virus (7.5xl0' ill) administration re-
sulted in minor lesions varying from mostly cystic lesions to microscopic 
foci of necrosis. The severe toxicity found by the latter investigators may 
result from differences in virus-batch solution, transgene containing vec-
tors or the use of cortocosteroids. 
Conclusion 
We report in this study the relatively limited dose dependent neuro-
toxicity observed after adenoviral TKlGCV administration in a rat model. 
The toxicity observed was generally limited to the injection area. Systemic 
toxicity of the virus was absent. Previous studies have shown the thera-
peutic effectiveness of recombinant adenoviral vector harboring the HSV-
tk gene in the treatment of brain tumors and leptomeningeal metastases. 
Clinical application of this approach is therefore considered acceptable. 
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General discussion 
Introduction 
Thls thesis shows the effectiveness and feasibility of treating experimental 
CNS tumors in rats with recombinant adenovirus harbouring the HSV-tk 
gene and subsequent GCV. We concluded that based on these data, clini-
cal application of thls approach is considered acceptable. Phase 1 clinical 
trials using recombinant adenovirus-TK and subsequent GCV admini-
stration in humans with recurrent glioblastoma are starting at the moment 
or are already under investigation (1). A few aspects concerning the appli-
cation of the adenovirus in human brain tumors and future prospects are 
discussed. 
Adenoviral veClors 
\Ve used the recombinant adenoviral vector in our experiments because 
of the advantages over other viruses. High titers of the adenovirus can be 
obtained and the cell-free virus can be injected directly into the tumor or 
the CSF where an effective spread of the virus is established. Both divid-
ing and non- dividing cells can be infected by the vector wich is an im-
portant advantage over retroviral vectors, since the majority of cells in 
human malignant brain tumors are in GO phase. Furthermore, insertional 
mutagenesis by an adenoviral vector is unlikely because the DNA remains 
extrachromosomally. The immunological toxicity in rats found in our 
study (chapter 6) could be the only constraint when using the virus for 
clinical application. However, the inflammatory reaction observed after 
intracerebral injections of hlgh titers of the vector is not comparable to the 
damage and inflammatory reaction inflicted by surgical resection or irra-
diation of brain tumors. In addition, the inflammatory response can par-
tially be suppressed in humans by the use of standard peri-operative 
corticosteroids. Therefore, in our opinion, the intracerebral immunologi-
cal toxicity can be regarded as an acceptable side-effect. 
Expen'mental model versus human bmin tumors 
Rat brain tumors are experimentally induced tumors which can not be 
compared in their biological behaviour to human brain tumors. The 9L 
rat brain tumor cells are mitotically very active and show only subtle inva-
sive growth into the brain parenchyma. The rat brain tumor model used 
in thls thesis has therefore more or less "ideal" features for the treatment 
with recombinant adenovirus-TK and subsequent GCV administration: 
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The mitotic activIty of these cells renders them very sensitive to the 
TKlGCV mechanism (this thesis) and the mild invasive growth makes the 
tumor very suitable for direct injection of the recombinant virus. Primary 
human brain tumors, for instance glioblastomas are aggressive infiltrating 
tumors that, although fast growing, are not comparable to the growth rate 
of the rat brain tumor in vivo. Secondly, the infiltration of glioblastoma 
cells into the brain parenchyma is very aggressive and extends sometimes 
to the other hemisphere (2,3). These infiltrating tumors are therefore not 
ideal for direct tumor injection of the recombinant virus since the infil-
trating cells cannot be reached via this route. However, recurrent 
glioblastoma usually occurs at the resection site. Regrowth could therefore 
be delayed or prevented in the resection area by direct injection of the 
vector in the tumorbed. This could theoretically lead to a longer survival 
of patients with glioblastoma. Total eradication of the tumor will be diffi-
cult to achieve since infiltrative cells at a large distance of the injection site 
will not be transfected after direct tumor injection with recombinant virus. 
Secondary brain tumors (metastases) show only mild infiltration and are 
therefore perhaps better candidates for direct injection of the tumorbed 
after tumor resection. Intrathecal injection of recombinant adenovirus has 
only value in the treatment ofleptomeningeal metastasis (chapter 4). 
Minimal residual disease 
Treatment of glioblastoma is nowadays usually confined to surgical resec-
tion followed by irradiation. Microsurgery and neuronavigation have im-
proved surgical techniques but did not improve survival of patients with 
glioblastoma. Adjuvant experimental therapies as described in this thesis 
can in my opinion only improve survival when a "minimal residual dis-
ease" is left. This means that a maximum of cytoreductive surgery should 
be performed (followed by post-operative irradiation) after wich an ex-
perimental adjuvant therapy can achieve its optimum effect. Trials should 
therefore be confined to patients in good neurological condition who pre-
sent with newly diagnosed primary brain tumors. In recurrent glioblas-
toma the disease is extended to a degree were it is unlikely to be 
controlled by experimental therapies. 
Targeting and new routes of administration 
Although gene therapy is still a promising new therapy, the delivery of the 
transgene to infiltrating brain tumor cells remains a major problem to 
overcome. New stratagies are being developed and are discussed shortly. 
Arterial (carotid) administration of virus (HSV, adenovirus) in combina-
tion with opening of the blood-brain barrier with bradykinin or mannitol 
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has been shown to transfect tumor cells selectively (4,5). This is probably 
due to fact that neovasculature in the tumor has a weaker blood-brain 
barrier as compared to the blood-brain barrier in normal brain. This route 
of administration could have some significant advantages over direct in-
jection of the vector since tumor cells over large areas can be transfected. 
Another interesting approach is the vector targeting of neovascularisation 
of the tumor (6). In theory, destruction of the tumor vasculature will in-
duce an anti-cancer effect. This approach has the advantage that also in-
filtrative growth of tumors can be arrested. Pressure perfusion of the 
interstitial space of brain parenchyma has been developed for the delivery 
of macromolecules to a large area surrounding the priroary brain tumor 
(7,8). This method could be of iroportance for the delivery of vectors to 
infiltrating tumor cells surrounding the primary tumor. Combinations of 
the delivery methods mentioned could be applied to achieve maximum 
tumor cell kill. Further effectivity of gene therapy for cancer can be ob-
tained by targeting the vector to tumor cell or tumor endothelium via re-
ceptor mediated augmented transfection (6). Replication competent 
recombinant adenoviruses have been demonstrated to induce an very ef-
fective tumor response (9). The virus could be of value in the treatment 
of infiltrating brain tumors although the toxicity of these viruses for nor-
mal tissue has to be assessed first. 
Conclusion 
Effective vector application to the tumor will be essential in the future for 
succesfull gene therapy for brain tumors. Methods to iroprove delivery 
should be investigated thoroughly. Vector targeting to tumorcells or tu-
mor neovascularisation should also be studied further. 
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Summary 
The feasibility and use of recombinant adenovirus for the treatment of 
experimental brain tumors and leptomeningeal metastases in rats has been 
investigated in the different studies in this thesis. Chapters 2,3,4 and 5 
contain the published (or submitted) articles of the different studies con-
ducted by our study group. 
In chapter 1 the different methods of gene transfer are outlined. Viral gene 
delivery methods have demonstrated to be very efficient as compared to 
non-viral gene delivery methods, althougb the latter have a higber safety 
profile. Construction, advantage and disadvantage of the most commonly 
used recombinant gene delivery viruses (retrovirus, adenovirus, herpes 
Simplex virus and adeno-associated virus) are discussed briefly. 
Chapter 2: In experimental gene therapy for cancer genes encoding sensi-
tizing enzymes are developed to mediate the formation of a cytotoxic drug 
from a non-toxic pro-drug in order to circumvent systemic toxicity. The 
most commonly used sensitizing trans gene is the Herpes Simplex Virus 
thymidine kinase gene, also called "suicide gene". After transfection to 
the nucleus the gene is transcribed to the thymidine kinase enzyme. This 
enzyme is able to convert non-toxic GCV into a toxic nucleoside ana-
logue, GCV- mono-phosphate. The nucleoside analogue prevents DNA 
elongation which results in cell death during replication. The system has 
the advantage that only dividing cells are killed after treatment with GCV. 
This has large potential in the treatment of CNS malignancies, since the 
majority of normal brain cells are non-dividing. Recombinant viral vectors 
(retrovirus, adenovirus, herpes simplex virus, adeno-associated virus) 
which have shown efficient brain tumor cell kill in vitro and in vivo using 
the TKlGCV system are discussed. 
In chapter 3 the effectivity of recombinant adenoviral gene transduction 
and tumor cell kill after TKlGCV treatment is investigated in vitro and in 
vivo. First, rat (9L) and human brain tumor (U251) cells were infected in 
vitro with recombinant adenovirus containing the LacZ marker gene. Very 
efficient gene transduction was observed after staining with fl-Gal in both 
cell lines, althougb higher activity was observed in human cells. The same 
virus was used to inject brain tumors in rats. After staining, microscopy of 
the brain slices showed very efficient transduction, mainly localized in 
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tumor regions adjacent to normal brain tissue. Microscopy revealed next 
to transduced tumor cells also transduced brain cells without cytopathic 
effects. Tumor cell kill in vitro was evaluated by infecting rat (9L) and 
human (U25 1 ) brain tumor cells with recombinant adenovirus containing 
the TK ''suicide'' gene followed by GCV administration. Very efficient 
cell kill was observed in both cell lines. Interestingly, human cells were 
killed more effectively as compared to rat cells. Finally, rats with brain 
tumors were treated with recombinant adenovirus containing the TK gene 
at different titers. Subsequently, the rats were injected with GCV for 10 
days. Survival in rats treated with TKlGCV was prolonged significantly 
and directly related to the amounts of virus injected intra-tumorally. We 
also treated rats harbouring a brain tumor with recombinant retrovirus-
TK producer cells. No difference in survival time was observed between 
recombinant adenovirus and recombinant retrovirus treated rats. Com-
paring between these recombinant viruses however is difficult. Recombi-
nant adenovirus has the advantage that a cell free virus can be injected 
directly in vivo and that also non-dividing cells can be infected and killed 
when becoming mitotically active. 
In chapter 4 the effectivity of treatment of leptomeningeal metastases in a 
rat model using recombinant adenovirus containing the TK gene is stud-
ied. First, a leptomeningeal metastases rat model was developed by in-
jecting 9L brain tumor cells subocipitally directly into the CSF. Rats 
injected with these tumors developed tumor nodules all along the neuraxis 
and died within 20 days. 
Four human tumor cell lines (A549; non-small cell lung carcinoma, 518-
A2 melanoma, GLC-I; small cell lungcarcinoma, U251; human glioma) 
and 1 rat brain tumor cell line (9L) were infected in vitro with different 
titers of recombinant adenovirus containing a luciferase gene to quantify 
gene expression. All cell lines showed very effective gene expression after 
infection with the virus. The same cell lines were also infected with differ-
ent amounts of recombinant adenovirus containing the TK "suicide" 
gene, followed by GCV administration to investigate tumor cell kill. All 
cell lines were very effectively killed by the virus. The study showed also 
that cell kill continued at least until 6 days after infection of the tumor 
cells and that human glioma cells (U251) were more effectively killed in 
time than rat brain tumor (9L) cells. 
In the in vivo experiments described in this chapter, rats with leptomen-
ingeal metastases were injected intrathecally (suboccipital) with recombi-
nant adenovirus harbouring the LacZ marker gene. The CNS was 
removed and stained with p-Gal to investigate gene transduction in lep-
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tomeningeal tumors and healthy tissue in vivo. Microscopic examination 
revealed transduced tumor cells all along the neuraxis. Most transduced 
cells were observed in the tumor mass near the injection site. A few epen-
dymal cells were also transduced, but no cytopathic effects were observed. 
Rats with leptomeningeal metastases were then injected intrathecally 
(suboccipital) with recombinant adenovirus containing the TK "suicide" 
gene. 24 hours after injection the animals were treated with GCV for 10 
days. Rats treated with TKlGCV lived significantly longer as compared to 
control animals. 
In chapter 5 adenoviral gene transfer and killing efficiency using the 
TKlGCV mechanism was evaluated in several human tumor cell lines 
occurring as central nervous system malignancies. The effectiveness was 
tested in vitro and in experimental rat brain tumors and leptomeningeal 
metastases models. 
Recombinant viruses with the transcription of genes under the control of 
either the major late promotor (MLP) or the human cytomegalovirus 
(CMV) immediate early gene promotor were constructed and compared 
for gene transfer and killing efficiency in vitro and in vivo. 
Human tumor cell lines occurring as brain metastases (A549; non-small 
cell lung carcinoma, 518-A2 melanoma, GLC-l; small cell lungcarci-
noma), three human glioma cell lines (U251, D384, LW5) and 1 rat 
glioma cell line (9L) were infected with recombinant adenovirus contain-
ing the LacZ marker gene in vitro. All cell lines were effectively transduced 
with the LacZ marker gene after infection. The same cell lines were also 
infected in vitro with different titers of recombinant adenovirus containing 
the TK "suicide" gene followed by GCV administration. All cell lines 
were very effectively killed by the virus. We also demonstrate that tumor 
cell doubling time of glioma cells was directly correlated to the killing 
efficiency ill vitro after TK/GCV treatment. The MLP and CMV promo-
tor showed a few differences in vitro and ill vivo. Tumor cells infected with 
recombinant adenovirus with the transcription under the control of the 
CMV promotor showed enlargement of cells as compared to the MLP 
promotor, suggesting toxicity. Most tumor cell lines were killed more 
efficiently after infection with adenovirus-TK containing the CMV pro-
motor as compared to the adenovirus containing the MLP promotor. 
However, the CMV promotor also showed a higher cell kill of glioma cells 
without GCV treatment, suggesting toxicity. In the in vivo experiments, 
rats with either leptomeningeal metastases or brain tumor were treated 
with different titers of recombinant adenovirus-TK containing either the 
MLP or the CMV promoter and subsequent GCV treatment. Rats with 
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brain tumor showed a dose dependent survival for both vectors and a 
better therapeutic effect after treatment with the CMV promotor was ob-
served as compared to the MLP promoter. Rats with leptomeningeal me-
tastases showed also a significant longer symptom free period after 
treatment with both vectors. Treatment with the CMV promoter showed 
also a significantly longer symptom free period as compared to the MLP 
promoter in the rats with leptomeningeal metastases. 
In chapter 6 intracerebral toxicity of recombinant adenovirus was exam-
ined histopathalogically. Also the systemic spread of virus after intracere-
bral injection was investigated. 
Rats were injected intracerebrally in the right frontal lobe with 108 or 109 
ill of recombinant adenovirus containing the TK gene, wild type adenovi-
rus or PBS as controls. The rats were than treated for 16 days with GCV 
or PBS as a control. The brains of the treated rats were then microscopi-
cally examined. Rats injected with 108 ill of recombinant virus showed 
only mild to moderate perivascular infiltration in the near vicinity of the 
injection site. Brains of animals injected with 109 ill's revealed moderate 
to severe perivascular lymphoid infiltration, glial proliferation, edema and 
parenchymal loss extending to basal, baso-Iateral and caudal area of the 
frontal lobe, but not exceeding a distance of 2-3 mm from the injection 
canal. An additional effect of GCV administration was not observed. 
Wild-type adenovirus injection revealed only slightly more severe lesions 
compared to those treated with 108 ill recombinant adenovirus. Systemic 
spread of the virus was studied after intracerebral injection of recombinant 
adenovirus containing the luciferase marker gene. The expression of the 
transgene was measured in brain, spinal cord, hart, lung liver, spleen, 
gastro-intestines, kidney and gonads, 3 and 14 days after intracerebral 
injection. Activity of the luciferase gene could only be detected in brain 
and spinal cord. In all other organs no detection of the transgene could be 
detected. 
General conclusions 
The studies in this thesis show an very efficient recombinant adenoviral 
gene transduction in various tumor cells ill vitro, occurring as CNS malig-
nancies. Efficient trans gene expression was also demonstrated in rat brain 
tumors and leptomeningeal metastases ill vivo. A high killing effectivity 
using the recombinant adenovirus containing tile HSV-tk gene and subse-
quent GCV administration was obtained in human and rat tumor cells ill 
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vitro. Significantly prolonged survival in rats with brain tumor or lep-
tomeningeal metastases was obtained after treatment with recombinant 
adenovirus-tk/GCV. Transgene expression and killing efficiency was dose 
dependent in vitro and in vivo. We also demonstrated that the promoter 
driving the trans gene in an adenoviral vector influences toxicity and effi-
ciency of treatment. In vivo toxicity studies showed only limited damage 
after intracerebral injection of recombinant adenovirus. Systemic trangene 
expression was not measured after intracerbral or intrathecal injection. 
Rats did not show clinical deteriation during or after treatment with the 
recombinant virus. 
The data show the effectiveness and feasibility of treating CNS tumors 
with recombinant adenovirus harbouring the HSV-tk gene and subse-
quent GCV. Based on these data, clinical application of this approach is 
therefore considered acceptable. 

Samenvatting 
In dit proefschrift wordt het gebruik van recombinant adenovirus voor de 
behandeling van experimentele hersen tumoren en leptomeningeale me-
tastasen in ratten onderzocht in verschillende studies. Hoofdstuk 2,3,4 en 
5 bevatten gepubliceerde (of nog te publiceren) artikelen van de verschll-
lende studies. 
In hoofdstuk 1 worden de verschlllende methoden van genoverdracht 
besproken. Het is aangetoont dat virale genoverdracht zeer efficient is 
t.o.v. niet virale genoverdracht methoden, hoewel de laatste een hoger 
veiligheids profie! hebben. Constructie, voordelen en nadelen van de 
meest gebruikte recombinant genoverdracht methoden (retrovirus, adeno-
virus, herpes Simplex virus en adeno-associated virus) worden kort be-
sproken. 
Hoofdstuk 2: in de experimentele gentherapie worden genen ontwikkeld 
die coderen voor enzymen die een niet toxische stof kunnen omzetten in 
een toxische stof zodat systemische toxiciteit kan worden vermeden. Het 
meest gebruikte gen hlervoor is het Herpes Simplex virus thymidine kina-
se gen (HSV-tk), ook wei "zelfmoord gen" genoemd. Na tranfectie in de 
kern van een cel wordt het gen omgezet in het thymidine kinase enzym. 
Dit enzym kan niet toxisch Ganciclovir (GCV) ornzetten in een toxisch 
nucleoside analoog, GCV-trifosfaat. Dit nucleoside analoog voorkomt 
DNA verlenging wat uitendelijk cel dood veroorzaakt als de cel in deling 
gaat. Het systeem heeft het voordeel dat aileen delende cellen worden 
gedood na behandeling met GCV. Dit kan een groot voordeel zijn bij de 
behandeling van maligniteiten van het centrale zenuwstelsel aangezien de 
meeste cellen in het centrale zenuwstelsel niet delen. Recombinant virale 
vectoren (retrovirus, adenovirus, herpes simplex virus, adeno-associated 
virus) die met het TKlGCV systeem reeds efficiente celdood van hersen-
tumorcellen hebben kunnen bewerkstelIigen in vitro en in vivo worden 
besproken in dit hoofdstuk. 
In hoofdstuk 3 wordt de effectiviteit van recombinant adenovirale gen 
transductie en tumor celdoding na TKlGCV behandeling onderzocht in 
vitro en in vivo. 
Allereerst werden ratten (9L) en humane hersentumorcellen (U251) 
gelnfecteerd in vitro met recombinant adenovirus die het LacZ marke-
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ringsgen bevatten. Zeer efficiente gen transductie werd geobserveerd na-
dat de cellen werden gekleurd middels p-Gal, hoewe1 een hogere activiteit 
van het gen werd geobserveerd in humane tumorcellen. Hetze1fde virus 
werd gebruikt om hersentumoren in ratten te injecteren. Na kleuring van 
het virus demonstreerde de hersencoupes macroscopisch zeer efficiente 
gentransductie die met name in de tumor is ge1ocaliseerd. Microscopisch 
onderzoek van de coupes demonstreerde behalve getransduceerde tumor-
cellen ook getransduceerde hersencellen zonder cytopathologisch effect. 
Tumor cel doding in vitro werd geevalueerd door ratten (9L) en humane 
(U251) hersentumorcellen te infecteren met recombinant adenovirus die 
het TK "ze1fmoord gen" bevatten en vervolgens te behandelen net GCV. 
Zeer efficiente tumor cell do ding werd geobserveerd in beide tumor cellij-
nen. Een bijzonderheid was dat humane tumorcellen effectiever werden 
gedood dan rattentumor cellen. Ten slotte werden ratten met hersentu-
moren geinjecteerd met verschillende hoeveelheden recombinant adenovi-
rus die het TK gen bevatten. Vervolgens werden de ratten 10 dagen lang 
intraperitoneaal geinjecteerd met GCV. Overleving van ratten behande1d 
met TKlGCV was significant verlengd en direct gerelateerd aan de hoe-
veelheid virus die werd ingespoten. Ratten met hersentumoren werden 
ook behandeld met recombinant retrovirus-TK producercellen. Geen 
verschil in overleving werd geobserveerd tussen recombinant adenovirus 
en recombinant retrovirus-TK producercellen behandelde ratten. Het 
vergelijken van deze recombinant virussen in echter moeilijk. Recombi-
nant adenovirus heeft het voordeel dat een celvrije oplossing direct in vivo 
kan worden geinjecteerd en dat ook niet delende tumor cellen kunnen 
worden ge'infecteerd en gedood als ze in de1ing gaan. 
In hoofdstuk 4 wordt de effectiviteit van de behandeling van leptomenin-
geale metastasen met behulp van recombinant adenovirus welke het TK 
gen bevat bestudeerd in een rat model. A1lereerst werd hiertoe een lepto-
meningeale metastasen rat model ontwikke1d door 9L ratten hersentumor 
cellen suboccipitaal direct in de liquor te injecteren. Ratten die geinjec-
teerd werden ontwikkelden tumoren door het hele CZS en overleden bin-
nen 20 dagen. 
Vier humane tumor cellen (A549; niet klein cellig long carcinoom, 518-
A2; melanoom, GLC-l; klein cellig long carcinoom, U251; humaan glio-
om) en 1 ratten hersen tumor cellijn (9L) werd geinfecteerd in vitro met 
verschi1lende hoeveelheden (titers) recombinant adenovirus die het lucife-
rase-gen bevatten om genexpressie te kwantificeren. Aile cellijnen demon-
streerden een zeer effectieve genexpressie na infectie met het virus. 
Dezelfde cell Hjnen werden ook geinfecteerd met verschillende titers re-
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combinant adenovirus-TK, gevolgd door GCV toediening om tumorcel-
do ding te kwantificeren. AIle cellijnen werden zeer effectief gedood door 
het virus. Het onderzoek toonde ook aan dat celdoding ten minste 6 da-
gen na infectie van de tumorcellen voortduurt en dat humane glioomcel-
len (U251) effectiever worden gedood per tijseenheid dan ratten 
hersentumor (9L) cell en. 
In de in vivo experimenten die in dit hoofdstuk worden beschreven, wor-
den ratten met leptomeningeale metastasen, intrathecaal (suboccipitaal) 
geinjecteerd met recombinant adenovirus die het LacZ markergen bevat-
ten. Het CZS werd verwijderd en gekleurd met p-GAL om gentransduc-
tie in leptomeningeale tumoren en gezond weefsel te onderzoeken. 
Microscopisch onderzoek toonde getransduceerde cellen langs de gehele 
neuraxis. De meeste getransduceerde cellen werden geobserveerd in de 
tumor massa dichtbij de injectie plaats. Hoewel enkele ependymcellen ook 
werden getransduceerd, werden geen cytopathologische effecten waarge-
nomen. Ratten met leptomeningeale metastasen werden vervolgens in-
thrathecaal (suboccipitaal) geinjecteerd met recombinant adenovirus-TK. 
24 na injectie werden de dieren 10 dagen behandeld met GCV. Ratten die 
behandeld werden met TKlGCV leefden significant langer dan controle-
ratten. 
In hoofstuk 5 wordt de adenovirale gen transfer en de TKlGCV dodings-
effectiviteit geevalueerd in diverse humane tumor cellijnen die voorkomen 
als maligniteiten binnen het CZS. De effectiviteit van het virus werd getest 
in vitro en in experimentele ratten hersentumoren en leptomeningeale 
metastasen modellen in vivo. 
Recombinant virussen met de transcriptie van transgenen door de "major 
late promotor" (MLP) of "human cytomegalovirus immediate early gene 
promotor" (CMV) werden eerst geconstrueerd en vervolgens vergeleken 
voor wat betreft gentransfer en dodingseffectiviteit in vitro en in vivo. Hu-
mane tumorcellijnen die voorkomen als hersenmetastasen (A549; niet 
kleincellig longcarcinoom, 518-A2; melanoom, GLC-l; kleincellig long-
carcinoom), 3 humane glioom cellen (U251, D384, LW5) en 1 ratten 
gliomacellijn (9L) werden geinfecteerd in vitro met het recombinant aden-
ovirus die LacZ markergen bevat. Aile cellijnen werden na infectie effectief 
getransduceerd met het LacZ gen. Dezelfde cellijnen werden in vitro ook 
geinfecteerd met verschillende titers recombinant adenovirus-TK gevolgd 
door GCV toediening. AIle cellijnen werden effectief gedood door het 
virus. Het onderzoek demonstreert ook dat tumorcel verdubbelingstijd 
van gliomacellen direct gecorreleerd is aan de dodingseffectiviteit in vitro 
na behandeling met TKlGCV. De MLP en CMV promotor lieten een 
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aantal verschillen zien in vitro en in vivo. Tumorcellen ge'infecteerd met 
recombinant adenovirus met de CMV promotor waren groter dan de cel-
len geinfecteerd met de MLP promotor wat zou kunnen duiden op toxi-
citeit. De meeste tumorcellen werden ook significant betel' gedood na 
infectie met adenovirus-TK die de CMV promotor bevatten dan de virus-
sen die de MLP promotor bevatten. Echter de CMV promotor demon-
streerde ook een hogere cell doding na infectie maar zonder GCV 
behandeling, wat duid op toxiciteit. In de in vivo experimenten werden 
ratten met leptomeningeale metastasen of een hersentumor geinjecteerd 
met verschillende titers recombinant adenovirus-TK die of de MLP of de 
CMV-promotor bevatten, en vervolgens behandeld met GCV. Ratten met 
een hersentumor demonstreerden een dosis afhankelijke significant ver-
lengde overleving na behandeling met beide vectoren, hoewel de CMV 
promotor een significant betel' therapeutisch effect bewerkstelligde in ver-
gelijking met de MLP promoter. Ratten met leptomeningeale metastasen 
hadden een significant langere symptoomvrije periode na behandeling met 
beide vectoren. Echter, ook hier bleek de behandeling met de CMV-
promotor een significant langere symtoom vrije periode te bewerkstelligen 
in vergelijking met de MLP-promotor. 
In hoofdstuk 6 werd de intracerebrale toxiciteit van recombinant adenovi-
rus histo-pathalogisch bestudeerd. Hiernaast werd ook de mogelijke syste-
mische verspreiding van het virus bestudeerd. Ratten werden intra cere-
braal geinjecteerd in de rechter frontaalkwab met 10' of 10' IV recombi-
nant adenovirus die het TK gen bevatten, wild-type adenovirus of PBS als 
controle. De ratten werden vervolgens 16 dagen lang behandeld met GCV 
of PBS als controle. De hersenen van behandelde ratten werden vervol-
gens microscopisch bestudeerd. Bij ratten die geinjecteerd waren met 10' 
"Infective Units" (IU) recombinant adenovirus werd aileen milde tot ma-
tige perivasculaire lymphoide infiltratie in de directe omgeving van de 
plaats van injectie waargenomen. Bij hersenen van ratten geinjecteerd met 
10' IU werd matige tot ernstige perivasculaire lymphoide infiltratie, gliale 
proliferatie, oedeem en parenchymverlies waargenomen die zich uibreidde 
naar basaal, baso-Iateraal en de caudaal van de frontaal kwab, maar zich 
niet verdeI' uitbreidde dan 2-3 mm vanaf het injectie kanaal. Een aanvul-
lend effect van GCV werd niet waal'genomen. Injectie van wild-type 
adenovirus demonstreerde iets meer uitgebreide leasies in vergelijking met 
de ratten behandeld met 10' IV recombinant adenovirus. Vervolgens werd 
de systemische verpreiding van het virus bestudeerd na intracerebrale in-
jectie van recombinant adenovirus die het luciferase-gen bevat. De expres-
sie van het transgen werd 3 en 14 dagen na intracerebrale injectie gemeten 
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in hersenweefsel, ruggemerg, hart, long, lever, milt, darmen, nier en tes-
tes. Luciferase activiteit was aileen meetbaar in hersenweefsel en rugge-
merg. In aile andere organen werd geen trangene activiteit gemeten. 
Algemene conclusies 
De studies in dit proefschrift laten een zeer effectieve gentransductie zien 
m. b. v recombinant adenovirus in diverse tumorcellen in vitro die voorko-
men als maligniteiten van het centrale zenuwstelsel. Effectieve genexpres-
sie werd ook aangetoont in ratten hersentumoren en leptomeningeale 
metastasen in vivo. Hoge dodingseffectiviteit kon worden bewerkstelligd 
in humane en ratten tumor cellen in vitro. Een significant verlengde over-
leving in ratten met hersentumoren of leptomeningeale metastasen kon 
worden bereikt na behandeling met recombinant adenovirus-tk/GCV be-
handeling. Transgen-expressie en dodingseffectiviteit was dosis afhanke-
Jijk zowel in vitro als in vivo. Er werd tevens aangetoond dat de promotor 
die het transgen aanstuurt in een adenovirale vector de toxiciteit en effec-
tiviteit van de behandeling bemvloed. Slechts beperkte schade werd na 
intracerebrale injectie van reconbinant adenovirus in de in vivo toxiciteits-
studies gevonden. Systemische transgen expressie werd niet gemeten na 
intracerebrale of intrathecale injectie. Ratten gingen niet klinisch achteruit 
tijdens of na de behandeling met recombinant adenovirus. 
Deze data laten de effectiviteit en geschiktheid om tumoren van het CZS 
te behandelen met recombinant adenovirus-tk en GCV. Gebaseerd op 
deze data is een klinische toepassing acceptabel. 
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adene associated virus 
human adenovirus; serotype 5 
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cytomegalovirus immediate early promoter 
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ganciclovir 
ganciclovir monophosphate 
ganciclovir triphosphate 
herpes simplex virus 
thymidine kinase-gene derived from the herpes simplex virus 
recombinant adenovirus containing the thymidine kinase 
transgene and mlp promoter; constructed and manufactured by 
Introgene 
inverted terminal repeats 
infectious units 
kilobase 
long terminal repeats 
luciferase 
major late promoter 
magnetic resonance imaging 
messenger RNA 
murine leukemia virus 
nuclear location signal 
phosphate buffered saline 
polymerase chain reaction 
plaque fonning units 
replicative competent retrovirus 
ribonucleic acid 
rous sarcoma virus 
standard deviation 
tymidine kinase 
vector producing cell line 
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Appendix: figures 
Chapter 3, figure 2a, 2b 
Microscopy of U251 and 9L tumor cells transduced with Ad.RSVj3gal 
(x20). Human U251 and 9L tumor cells were cultured and infected at 
confluency with an m.o.i. of 100. Seventy-two hours after infection, the 
wells were stained with X-Gal, washed and fixed. Almost all U251 tumor 
cells are stained blue in the nucleus (a). 9L tumor cells 3 days after infec-
tion with Ad.RSVbgal (xl0)(b). 














